|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions increases expression |
EXP |
[MGMT protein co-treated with ABCB1 protein] results in decreased susceptibility to Carmustine Carmustine results in increased expression of ABCB1 protein |
CTD |
PMID:11792417 PMID:15239124 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
affects response to substance |
EXP |
ABCC2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCG5 |
ATP binding cassette subfamily G member 5 |
affects response to substance |
EXP |
ABCG5 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865
|
|
G |
ACER2 |
alkaline ceramidase 2 |
increases expression |
ISO |
Carmustine results in increased expression of ACER2 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 9:19,409,009...19,452,505
Ensembl chr 9:19,409,009...19,452,505
|
|
G |
ACP3 |
acid phosphatase 3 |
decreases expression |
ISO |
Carmustine results in decreased expression of ACP3 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 3:132,317,407...132,368,302
Ensembl chr 3:132,317,369...132,368,302
|
|
G |
ACTC1 |
actin alpha cardiac muscle 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of ACTC1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr15:34,790,230...34,795,549
Ensembl chr15:34,790,107...34,795,589
|
|
G |
ACTG2 |
actin gamma 2, smooth muscle |
decreases expression |
EXP |
Carmustine results in decreased expression of ACTG2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 2:73,893,008...73,919,865
Ensembl chr 2:73,892,314...73,919,865
|
|
G |
ACTN1 |
actinin alpha 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of ACTN1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr14:68,874,128...68,979,302
Ensembl chr14:68,874,123...68,979,440
|
|
G |
ADAM15 |
ADAM metallopeptidase domain 15 |
decreases expression |
EXP |
Carmustine results in decreased expression of ADAM15 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:155,051,316...155,062,775
Ensembl chr 1:155,050,566...155,062,775
|
|
G |
ADAMTS4 |
ADAM metallopeptidase with thrombospondin type 1 motif 4 |
decreases expression |
EXP |
Carmustine results in decreased expression of ADAMTS4 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:161,184,302...161,199,054
Ensembl chr 1:161,184,302...161,199,054
|
|
G |
ADCYAP1 |
adenylate cyclase activating polypeptide 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of ADCYAP1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr18:904,411...912,172
Ensembl chr18:904,871...912,172
|
|
G |
ADRA1B |
adrenoceptor alpha 1B |
decreases expression |
EXP |
Carmustine results in decreased expression of ADRA1B mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 5:159,865,086...159,989,205
Ensembl chr 5:159,865,080...159,973,012
|
|
G |
AGR3 |
anterior gradient 3, protein disulphide isomerase family member |
affects response to substance |
EXP |
AGR3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 7:16,854,681...16,881,983
Ensembl chr 7:16,859,412...16,881,987
|
|
G |
AGT |
angiotensinogen |
decreases response to substance |
EXP |
AGT protein mutant form results in decreased susceptibility to Carmustine; AGT protein results in decreased susceptibility to Carmustine |
CTD |
PMID:11034089 |
|
NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576
|
|
G |
AKR1B1 |
aldo-keto reductase family 1 member B |
affects response to substance |
EXP |
AKR1B1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 7:134,442,350...134,459,239
Ensembl chr 7:134,442,356...134,459,284
|
|
G |
AKR1C1 |
aldo-keto reductase family 1 member C1 |
affects response to substance |
EXP |
AKR1C1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr10:4,963,415...4,983,283
Ensembl chr10:4,963,253...4,983,283
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions affects response to substance |
ISO EXP |
Carmustine results in decreased phosphorylation of AKT1 protein LCN2 protein promotes the reaction [Carmustine results in decreased phosphorylation of AKT1 protein] AKT1 protein affects the susceptibility to Carmustine |
CTD |
PMID:18430789 PMID:19860839 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759
|
|
G |
AKT2 |
AKT serine/threonine kinase 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of AKT2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:40,230,317...40,285,345
Ensembl chr19:40,230,317...40,285,536
|
|
G |
ALAD |
aminolevulinate dehydratase |
decreases expression multiple interactions |
EXP |
Carmustine results in decreased expression of ALAD mRNA [Cyclophosphamide co-treated with Carmustine co-treated with Etoposide] results in decreased activity of ALAD protein |
CTD |
PMID:15980968 PMID:19162187 |
|
NCBI chr 9:113,386,312...113,401,284
Ensembl chr 9:113,386,312...113,401,290
|
|
G |
ALAS2 |
5'-aminolevulinate synthase 2 |
decreases expression |
ISO |
Carmustine results in decreased expression of ALAS2 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr X:55,009,055...55,030,977
Ensembl chr X:55,009,055...55,030,977
|
|
G |
ALDH1A3 |
aldehyde dehydrogenase 1 family member A3 |
affects response to substance |
EXP |
ALDH1A3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr15:100,879,831...100,916,626
Ensembl chr15:100,861,924...100,916,626
|
|
G |
ALOX12 |
arachidonate 12-lipoxygenase, 12S type |
affects response to substance decreases expression |
ISO |
ALOX12 protein affects the susceptibility to Carmustine Carmustine results in decreased expression of ALOX12 mRNA |
CTD |
PMID:16005536 PMID:19373248 |
|
NCBI chr17:6,996,049...7,010,754
Ensembl chr17:6,996,049...7,010,754
|
|
G |
ALOX15B |
arachidonate 15-lipoxygenase type B |
decreases expression |
EXP |
Carmustine results in decreased expression of ALOX15B mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:8,039,059...8,049,134
Ensembl chr17:8,039,034...8,049,134
|
|
G |
AMH |
anti-Mullerian hormone |
decreases expression |
EXP |
Carmustine results in decreased expression of AMH mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:2,249,323...2,252,073
Ensembl chr19:2,249,309...2,252,073
|
|
G |
ANK2 |
ankyrin 2 |
affects response to substance |
EXP |
ANK2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 4:112,705,622...113,383,736
Ensembl chr 4:112,818,032...113,384,221
|
|
G |
ANKRD1 |
ankyrin repeat domain 1 |
affects response to substance |
EXP |
ANKRD1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr10:90,912,096...90,921,087
Ensembl chr10:90,912,096...90,921,087
|
|
G |
AP1S2 |
adaptor related protein complex 1 subunit sigma 2 |
affects response to substance |
EXP |
AP1S2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr X:15,825,806...15,854,813
Ensembl chr X:15,825,806...15,854,931
|
|
G |
APC |
APC regulator of WNT signaling pathway |
affects response to substance |
EXP |
APC mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 5:112,707,498...112,846,239
Ensembl chr 5:112,707,518...112,846,239
|
|
G |
APC2 |
APC regulator of WNT signaling pathway 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of APC2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:1,446,230...1,473,244
Ensembl chr19:1,446,302...1,473,244
|
|
G |
APEX1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases response to substance decreases response to substance |
EXP |
APEX1 protein mutant form results in increased susceptibility to Carmustine APEX1 protein results in decreased susceptibility to Carmustine |
CTD |
PMID:12231548 PMID:16243814 PMID:17259346 PMID:19470598 |
|
NCBI chr14:20,455,226...20,457,767
Ensembl chr14:20,455,191...20,457,772
|
|
G |
APLNR |
apelin receptor |
decreases expression |
EXP |
Carmustine results in decreased expression of APLNR mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:57,233,591...57,237,250
Ensembl chr11:57,233,577...57,237,250
|
|
G |
AQP8 |
aquaporin 8 |
decreases expression |
EXP |
Carmustine results in decreased expression of AQP8 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr16:25,216,947...25,228,932
Ensembl chr16:25,215,731...25,228,932
|
|
G |
ARF1 |
ARF GTPase 1 |
affects response to substance |
EXP |
ARF1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:228,082,708...228,099,212
Ensembl chr 1:228,082,708...228,099,212
|
|
G |
ARPC2 |
actin related protein 2/3 complex subunit 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of ARPC2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 2:218,217,189...218,254,348
Ensembl chr 2:218,217,141...218,254,356
|
|
G |
ARRDC2 |
arrestin domain containing 2 |
affects response to substance |
EXP |
ARRDC2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr19:18,001,124...18,014,102
Ensembl chr19:18,001,132...18,014,102
|
|
G |
ARTN |
artemin |
decreases expression |
EXP |
Carmustine results in decreased expression of ARTN mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:43,933,801...43,937,240
Ensembl chr 1:43,933,320...43,937,240
|
|
G |
ASMTL |
acetylserotonin O-methyltransferase like |
decreases expression |
EXP |
Carmustine results in decreased expression of ASMTL mRNA |
CTD |
PMID:15980968 |
|
NCBI chr X:1,403,139...1,453,756 NCBI chr Y:1,403,139...1,453,756
Ensembl chr Y:1,403,139...1,453,762 Ensembl chr X:1,403,139...1,453,762
|
|
G |
ATP1A3 |
ATPase Na+/K+ transporting subunit alpha 3 |
decreases expression |
EXP |
Carmustine results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:41,966,582...41,994,230
Ensembl chr19:41,966,582...41,997,497
|
|
G |
ATP4B |
ATPase H+/K+ transporting subunit beta |
decreases expression |
EXP |
Carmustine results in decreased expression of ATP4B mRNA |
CTD |
PMID:15980968 |
|
NCBI chr13:113,648,804...113,658,198
Ensembl chr13:113,648,804...113,658,198
|
|
G |
ATP5F1D |
ATP synthase F1 subunit delta |
decreases expression |
EXP |
Carmustine results in decreased expression of ATP5F1D mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:1,241,751...1,244,825
Ensembl chr19:1,241,746...1,244,825
|
|
G |
ATP6V0C |
ATPase H+ transporting V0 subunit c |
decreases expression |
EXP |
Carmustine results in decreased expression of ATP6V0C mRNA |
CTD |
PMID:15980968 |
|
NCBI chr16:2,513,726...2,520,218
Ensembl chr16:2,513,952...2,520,218
|
|
G |
ATR |
ATR serine/threonine kinase |
multiple interactions |
EXP |
ATR protein affects the reaction [Carmustine results in increased phosphorylation of and results in increased activity of CHEK1 protein] |
CTD |
PMID:19261750 |
|
NCBI chr 3:142,449,235...142,578,733
Ensembl chr 3:142,449,007...142,578,733
|
|
G |
ATXN2L |
ataxin 2 like |
decreases expression |
EXP |
Carmustine results in decreased expression of ATXN2L mRNA |
CTD |
PMID:15980968 |
|
NCBI chr16:28,822,999...28,837,232
Ensembl chr16:28,822,999...28,837,237
|
|
G |
AVPR1A |
arginine vasopressin receptor 1A |
increases expression |
EXP |
Carmustine results in increased expression of AVPR1A mRNA |
CTD |
PMID:15980968 |
|
NCBI chr12:63,142,759...63,151,201
Ensembl chr12:63,142,759...63,151,201
|
|
G |
B4GALT5 |
beta-1,4-galactosyltransferase 5 |
decreases expression |
EXP |
Carmustine results in decreased expression of B4GALT5 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr20:49,632,945...49,713,878
Ensembl chr20:49,632,945...49,713,878
|
|
G |
BAIAP2 |
BAR/IMD domain containing adaptor protein 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of BAIAP2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:81,035,151...81,117,434
Ensembl chr17:81,035,122...81,117,434
|
|
G |
BAIAP3 |
BAI1 associated protein 3 |
decreases expression |
EXP |
Carmustine results in decreased expression of BAIAP3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr16:1,333,645...1,349,439
Ensembl chr16:1,333,638...1,349,439
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Carmustine results in increased expression of BAX protein |
CTD |
PMID:20920327 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL10 |
BCL10 immune signaling adaptor |
increases expression |
EXP |
Carmustine results in increased expression of BCL10 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:85,265,776...85,276,632
Ensembl chr 1:85,265,776...85,276,632
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions affects response to substance decreases expression |
EXP |
[Fenretinide co-treated with Carmustine] results in decreased expression of BCL2 protein BCL2 protein affects the susceptibility to Carmustine Carmustine results in decreased expression of BCL2 protein |
CTD |
PMID:15332326 PMID:16187019 PMID:18430789 PMID:20920327 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
affects response to substance decreases expression multiple interactions |
EXP ISO |
BCL2L1 protein affects the susceptibility to Carmustine Carmustine results in decreased expression of BCL2L1 protein [Fenretinide co-treated with Carmustine] results in decreased expression of BCL2L1 protein Carmustine results in decreased expression of BCL2L1 mRNA; Carmustine results in decreased expression of BCL2L1 protein |
CTD |
PMID:15332326 PMID:16187019 PMID:19860839 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BECN1 |
beclin 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of BECN1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
|
|
G |
BICD1 |
BICD cargo adaptor 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of BICD1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr12:32,106,847...32,383,633
Ensembl chr12:32,106,835...32,383,633
|
|
G |
BLK |
BLK proto-oncogene, Src family tyrosine kinase |
decreases expression |
EXP |
Carmustine results in decreased expression of BLK mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 8:11,494,387...11,564,599
Ensembl chr 8:11,486,894...11,564,599
|
|
G |
BMAL1 |
basic helix-loop-helix ARNT like 1 |
decreases expression |
ISO |
Carmustine results in decreased expression of BMAL1 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr11:13,276,652...13,387,266
Ensembl chr11:13,276,652...13,387,266
|
|
G |
BMP5 |
bone morphogenetic protein 5 |
affects response to substance |
EXP |
BMP5 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 6:55,753,653...55,875,590
Ensembl chr 6:55,753,653...55,875,590
|
|
G |
BMP7 |
bone morphogenetic protein 7 |
decreases expression |
EXP |
Carmustine results in decreased expression of BMP7 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr20:57,168,753...57,266,641
Ensembl chr20:57,168,753...57,266,641
|
|
G |
BRF1 |
BRF1 general transcription factor IIIB subunit |
decreases expression |
EXP |
Carmustine results in decreased expression of BRF1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr14:105,209,286...105,315,589
Ensembl chr14:105,209,286...105,315,589
|
|
G |
CA6 |
carbonic anhydrase 6 |
decreases expression |
EXP |
Carmustine results in decreased expression of CA6 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:8,945,868...8,975,092
Ensembl chr 1:8,945,867...8,975,092
|
|
G |
CADM1 |
cell adhesion molecule 1 |
affects response to substance |
EXP |
CADM1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr11:115,169,236...115,504,415
Ensembl chr11:115,169,218...115,504,957
|
|
G |
CALB2 |
calbindin 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of CALB2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr16:71,358,723...71,390,433
Ensembl chr16:71,358,713...71,390,436
|
|
G |
CASP3 |
caspase 3 |
increases activity multiple interactions increases cleavage increases expression |
ISO EXP |
Carmustine results in increased activity of CASP3 protein [Carmustine co-treated with 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid] results in increased activity of CASP3 protein; Disulfiram promotes the reaction [Carmustine results in increased cleavage of CASP3 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Carmustine results in increased activity of and results in increased cleavage of CASP3 protein]; [LCN2 protein co-treated with Carmustine] results in increased cleavage of and results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Carmustine results in increased activity of and results in increased cleavage of CASP3 protein]; Carmustine results in increased activity of and results in increased cleavage of CASP3 protein; pyrazolanthrone inhibits the reaction [Carmustine results in increased activity of and results in increased cleavage of CASP3 protein]; Zinc Sulfate inhibits the reaction [Carmustine results in increased activity of CASP3 protein] Carmustine results in increased expression of CASP3 protein |
CTD |
PMID:18590702 PMID:19860839 PMID:20046642 PMID:20920327 PMID:21600974 PMID:24193513 More...
|
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CAT |
catalase |
decreases activity multiple interactions |
ISO |
Carmustine results in decreased activity of CAT protein Acetylcysteine inhibits the reaction [Carmustine results in decreased activity of CAT protein] |
CTD |
PMID:20332008 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
affects activity affects response to substance decreases expression increases expression |
EXP |
Carmustine affects the activity of CCL2 protein CCL2 mRNA affects the susceptibility to Carmustine Carmustine results in decreased expression of CCL2 protein Carmustine results in increased expression of CCL2 mRNA |
CTD |
PMID:15980968 PMID:16365179 PMID:17522861 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CCN4 |
cellular communication network factor 4 |
affects response to substance |
EXP |
CCN4 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 8:133,191,039...133,231,690
Ensembl chr 8:133,191,039...133,231,690
|
|
G |
CCND1 |
cyclin D1 |
affects response to substance |
EXP |
CCND1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCNE1 |
cyclin E1 |
increases expression |
ISO |
Carmustine results in increased expression of CCNE1 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312
|
|
G |
CD151 |
CD151 molecule (Raph blood group) |
decreases expression |
EXP |
Carmustine results in decreased expression of CD151 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:832,952...838,831
Ensembl chr11:832,887...839,831
|
|
G |
CD44 |
CD44 molecule (IN blood group) |
affects response to substance |
EXP |
CD44 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402
|
|
G |
CD68 |
CD68 molecule |
decreases expression |
EXP |
Carmustine results in decreased expression of CD68 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:7,579,638...7,582,111
Ensembl chr17:7,579,491...7,582,111
|
|
G |
CD79A |
CD79a molecule |
decreases expression |
EXP |
Carmustine results in decreased expression of CD79A mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:41,877,279...41,881,372
Ensembl chr19:41,877,279...41,881,372
|
|
G |
CD80 |
CD80 molecule |
increases expression |
EXP |
Carmustine results in increased expression of CD80 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 3:119,524,293...119,559,614
Ensembl chr 3:119,524,293...119,559,614
|
|
G |
CDC25B |
cell division cycle 25B |
decreases expression |
ISO |
Carmustine results in decreased expression of CDC25B mRNA |
CTD |
PMID:16005536 |
|
NCBI chr20:3,786,951...3,806,115
Ensembl chr20:3,786,772...3,806,121
|
|
G |
CDH13 |
cadherin 13 |
affects response to substance |
EXP |
CDH13 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr16:82,626,969...83,800,640
Ensembl chr16:82,626,965...83,800,640
|
|
G |
CDK8 |
cyclin dependent kinase 8 |
decreases expression |
EXP |
Carmustine results in decreased expression of CDK8 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr13:26,254,129...26,405,238
Ensembl chr13:26,254,104...26,420,982
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
multiple interactions increases expression |
EXP |
[Carmustine co-treated with O(6)-benzylguanine] results in increased expression of CDKN1A protein; MDM4 protein promotes the reaction [Carmustine results in increased expression of CDKN1A protein] |
CTD |
PMID:15735757 PMID:16193384 PMID:18632648 PMID:20472715 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,397
|
|
G |
CDKN1C |
cyclin dependent kinase inhibitor 1C |
affects response to substance |
EXP |
CDKN1C mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr11:2,883,218...2,885,775
Ensembl chr11:2,883,213...2,885,775
|
|
G |
CDKN2A |
cyclin dependent kinase inhibitor 2A |
increases response to substance |
EXP |
CDKN2A protein results in increased susceptibility to Carmustine |
CTD |
PMID:16786135 |
|
NCBI chr 9:21,967,752...21,995,324
Ensembl chr 9:21,967,752...21,995,301
|
|
G |
CDKN3 |
cyclin dependent kinase inhibitor 3 |
decreases expression |
ISO |
Carmustine results in decreased expression of CDKN3 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr14:54,397,007...54,420,218
Ensembl chr14:54,396,849...54,420,218
|
|
G |
CDX4 |
caudal type homeobox 4 |
decreases expression |
EXP |
Carmustine results in decreased expression of CDX4 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr X:73,447,053...73,455,171
Ensembl chr X:73,447,053...73,455,171
|
|
G |
CEACAM3 |
CEA cell adhesion molecule 3 |
decreases expression |
EXP |
Carmustine results in decreased expression of CEACAM3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:41,796,587...41,811,554
Ensembl chr19:41,796,587...41,811,554
|
|
G |
CEBPB |
CCAAT enhancer binding protein beta |
decreases expression |
EXP |
Carmustine results in decreased expression of CEBPB mRNA |
CTD |
PMID:15980968 |
|
NCBI chr20:50,190,583...50,192,690
Ensembl chr20:50,190,734...50,192,690
|
|
G |
CGREF1 |
cell growth regulator with EF-hand domain 1 |
increases expression |
ISO |
Carmustine results in increased expression of CGREF1 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 2:27,099,353...27,119,128
Ensembl chr 2:27,098,889...27,119,128
|
|
G |
CHD2 |
chromodomain helicase DNA binding protein 2 |
affects response to substance |
EXP |
CHD2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr15:92,900,324...93,027,996
Ensembl chr15:92,886,203...93,027,996
|
|
G |
CHEK1 |
checkpoint kinase 1 |
multiple interactions |
EXP |
ATR protein affects the reaction [Carmustine results in increased phosphorylation of and results in increased activity of CHEK1 protein]; Caffeine inhibits the reaction [Carmustine results in increased phosphorylation of and results in increased activity of CHEK1 protein]; Carmustine results in increased phosphorylation of and results in increased activity of CHEK1 protein; O(6)-benzylguanine promotes the reaction [Carmustine results in increased phosphorylation of and results in increased activity of CHEK1 protein]; Wortmannin inhibits the reaction [Carmustine results in increased phosphorylation of and results in increased activity of CHEK1 protein] |
CTD |
PMID:19261750 |
|
NCBI chr11:125,625,136...125,681,124
Ensembl chr11:125,625,163...125,676,255
|
|
G |
CHRM4 |
cholinergic receptor muscarinic 4 |
decreases expression |
EXP |
Carmustine results in decreased expression of CHRM4 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:46,383,789...46,391,776
Ensembl chr11:46,383,789...46,391,776
|
|
G |
CHRNB3 |
cholinergic receptor nicotinic beta 3 subunit |
decreases expression |
EXP |
Carmustine results in decreased expression of CHRNB3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 8:42,697,366...42,737,407
Ensembl chr 8:42,697,366...42,737,407
|
|
G |
CHRNG |
cholinergic receptor nicotinic gamma subunit |
decreases expression |
EXP |
Carmustine results in decreased expression of CHRNG mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 2:232,539,692...232,548,115
Ensembl chr 2:232,539,692...232,548,115
|
|
G |
CKM |
creatine kinase, M-type |
decreases expression |
EXP |
Carmustine results in decreased expression of CKM mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:45,306,413...45,322,875
Ensembl chr19:45,306,413...45,322,875
|
|
G |
CLIC1 |
chloride intracellular channel 1 |
multiple interactions decreases response to substance |
EXP |
[4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid results in decreased activity of CLIC1 protein] which results in increased susceptibility to Carmustine CLIC1 protein results in decreased susceptibility to Carmustine |
CTD |
PMID:18590702 |
|
NCBI chr 6:31,730,581...31,737,318
Ensembl chr 6:31,730,581...31,739,763
|
|
G |
CLTCL1 |
clathrin heavy chain like 1 |
increases expression |
EXP |
Carmustine results in increased expression of CLTCL1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr22:19,179,473...19,291,719
Ensembl chr22:19,179,473...19,291,719
|
|
G |
CNTNAP1 |
contactin associated protein 1 |
increases expression |
EXP |
Carmustine results in increased expression of CNTNAP1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:42,682,531...42,699,993
Ensembl chr17:42,682,531...42,699,993
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
affects response to substance |
EXP |
COL1A1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632
|
|
G |
COL5A3 |
collagen type V alpha 3 chain |
decreases expression |
ISO |
Carmustine results in decreased expression of COL5A3 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr19:9,959,561...10,010,504
Ensembl chr19:9,959,561...10,010,504
|
|
G |
COL9A1 |
collagen type IX alpha 1 chain |
decreases expression |
EXP |
Carmustine results in decreased expression of COL9A1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 6:70,215,061...70,303,084
Ensembl chr 6:70,216,040...70,303,084
|
|
G |
COX6A2 |
cytochrome c oxidase subunit 6A2 |
decreases expression |
EXP |
Carmustine results in decreased expression of COX6A2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr16:31,427,731...31,428,360
Ensembl chr16:31,427,731...31,428,360
|
|
G |
CRABP1 |
cellular retinoic acid binding protein 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of CRABP1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr15:78,340,353...78,348,225
Ensembl chr15:78,340,353...78,348,225
|
|
G |
CRAT |
carnitine O-acetyltransferase |
decreases expression |
EXP |
Carmustine results in decreased expression of CRAT mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 9:129,094,794...129,110,793
Ensembl chr 9:129,094,142...129,111,189
|
|
G |
CRYBB1 |
crystallin beta B1 |
decreases expression |
EXP |
Carmustine results in decreased expression of CRYBB1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr22:26,599,278...26,618,027
Ensembl chr22:26,599,278...26,618,027
|
|
G |
CSF2 |
colony stimulating factor 2 |
affects response to substance |
EXP |
CSF2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170
|
|
G |
CSGALNACT1 |
chondroitin sulfate N-acetylgalactosaminyltransferase 1 |
affects response to substance |
EXP |
CSGALNACT1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 8:19,404,161...19,757,908
Ensembl chr 8:19,404,161...19,758,029
|
|
G |
CSRP3 |
cysteine and glycine rich protein 3 |
affects response to substance |
EXP |
CSRP3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr11:19,182,030...19,201,983
Ensembl chr11:19,182,030...19,210,571
|
|
G |
CST5 |
cystatin D |
decreases expression |
EXP |
Carmustine results in decreased expression of CST5 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr20:23,875,934...23,879,748
Ensembl chr20:23,875,934...23,879,748
|
|
G |
CTF1 |
cardiotrophin 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of CTF1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr16:30,895,846...30,903,560
Ensembl chr16:30,896,614...30,903,547
|
|
G |
CTNNAL1 |
catenin alpha like 1 |
increases expression |
EXP |
Carmustine results in increased expression of CTNNAL1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 9:108,942,577...109,013,499
Ensembl chr 9:108,942,569...109,013,522
|
|
G |
CTSL |
cathepsin L |
increases expression |
ISO |
Carmustine results in increased expression of CTSL mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469
|
|
G |
CUX2 |
cut like homeobox 2 |
affects expression |
ISO |
Carmustine affects the expression of CUX2 mRNA |
CTD |
PMID:19174181 |
|
NCBI chr12:111,034,165...111,350,554
Ensembl chr12:111,034,165...111,350,554
|
|
G |
CXCL1 |
C-X-C motif chemokine ligand 1 |
affects response to substance |
EXP |
CXCL1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308
|
|
G |
CXCL2 |
C-X-C motif chemokine ligand 2 |
affects response to substance |
EXP |
CXCL2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196
|
|
G |
CYP19A1 |
cytochrome P450 family 19 subfamily A member 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions |
EXP |
CYP3A4 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] |
CTD |
PMID:16087946 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
multiple interactions |
EXP |
CYP3A5 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] |
CTD |
PMID:16087946 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
|
|
G |
CYTH1 |
cytohesin 1 |
increases expression |
EXP |
Carmustine results in increased expression of CYTH1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:78,674,048...78,782,273
Ensembl chr17:78,674,048...78,782,297
|
|
G |
DEF6 |
DEF6 guanine nucleotide exchange factor |
affects response to substance |
EXP |
DEF6 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 6:35,297,818...35,321,771
Ensembl chr 6:35,297,818...35,321,771
|
|
G |
DHRS3 |
dehydrogenase/reductase 3 |
affects response to substance |
EXP |
DHRS3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:12,567,910...12,618,210
Ensembl chr 1:12,567,909...12,620,133
|
|
G |
DHX16 |
DEAH-box helicase 16 |
decreases expression |
EXP |
Carmustine results in decreased expression of DHX16 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 6:30,653,127...30,673,006
Ensembl chr 6:30,653,119...30,673,006
|
|
G |
DHX37 |
DEAH-box helicase 37 |
affects response to substance |
EXP |
DHX37 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr12:124,946,826...124,989,131
Ensembl chr12:124,946,825...124,989,131
|
|
G |
DKK1 |
dickkopf WNT signaling pathway inhibitor 1 |
increases response to substance |
EXP |
DKK1 protein results in increased susceptibility to Carmustine |
CTD |
PMID:20920327 |
|
NCBI chr10:52,314,281...52,317,657
Ensembl chr10:52,314,281...52,318,042
|
|
G |
DMRTC2 |
DMRT like family C2 |
affects response to substance |
EXP |
DMRTC2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr19:41,844,916...41,852,333
Ensembl chr19:41,844,743...41,852,333
|
|
G |
DNA2 |
DNA replication helicase/nuclease 2 |
affects response to substance |
EXP |
DNA2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr10:68,414,064...68,472,521
Ensembl chr10:68,414,064...68,472,121
|
|
G |
DNASE1L2 |
deoxyribonuclease 1 like 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of DNASE1L2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr16:2,236,444...2,238,711
Ensembl chr16:2,235,816...2,238,711
|
|
G |
DTX2P1-UPK3BP1-PMS2P11 |
DTX2P1-UPK3BP1-PMS2P11 readthrough, transcribed pseudogene |
decreases expression |
EXP |
Carmustine results in decreased expression of DTX2P1-UPK3BP1-PMS2P11 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 7:76,980,822...77,023,761
Ensembl chr 7:76,959,835...77,198,626
|
|
G |
DVL1 |
dishevelled segment polarity protein 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of DVL1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:1,335,278...1,349,418
Ensembl chr 1:1,335,276...1,349,418
|
|
G |
DYRK1B |
dual specificity tyrosine phosphorylation regulated kinase 1B |
affects response to substance |
EXP |
DYRK1B mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr19:39,825,350...39,834,162
Ensembl chr19:39,825,350...39,834,201
|
|
G |
E2F1 |
E2F transcription factor 1 |
increases expression |
EXP |
Carmustine results in increased expression of E2F1 protein |
CTD |
PMID:18632648 |
|
NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385
|
|
G |
ECM2 |
extracellular matrix protein 2 |
increases expression |
EXP |
Carmustine results in increased expression of ECM2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 9:92,493,547...92,559,106
Ensembl chr 9:92,493,554...92,536,655
|
|
G |
EDNRA |
endothelin receptor type A |
affects response to substance |
EXP |
EDNRA mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 4:147,481,097...147,544,954
Ensembl chr 4:147,480,917...147,544,954
|
|
G |
EEF1G |
eukaryotic translation elongation factor 1 gamma |
increases expression |
EXP |
Carmustine results in increased expression of EEF1G mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:62,559,596...62,573,891
Ensembl chr11:62,559,596...62,574,086
|
|
G |
EIF2B1 |
eukaryotic translation initiation factor 2B subunit alpha |
increases expression |
EXP |
Carmustine results in increased expression of EIF2B1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr12:123,620,406...123,633,686
Ensembl chr12:123,620,406...123,633,766
|
|
G |
EIF4A2 |
eukaryotic translation initiation factor 4A2 |
affects response to substance |
EXP |
EIF4A2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 3:186,783,577...186,789,897
Ensembl chr 3:186,783,205...186,789,897
|
|
G |
EIF6 |
eukaryotic translation initiation factor 6 |
decreases expression |
EXP |
Carmustine results in decreased expression of EIF6 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr20:35,278,906...35,284,772
Ensembl chr20:35,278,907...35,284,985
|
|
G |
ELMO1 |
engulfment and cell motility 1 |
affects response to substance |
EXP |
ELMO1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 7:36,852,906...37,449,326
Ensembl chr 7:36,852,906...37,449,223
|
|
G |
ENC1 |
ectodermal-neural cortex 1 |
increases expression |
ISO |
Carmustine results in increased expression of ENC1 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 5:74,627,409...74,640,728
Ensembl chr 5:74,627,406...74,641,424
|
|
G |
EPHX1 |
epoxide hydrolase 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of EPHX1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563
|
|
G |
ESPN |
espin |
increases expression |
ISO |
Carmustine results in increased expression of ESPN mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 1:6,424,776...6,461,370
Ensembl chr 1:6,424,776...6,461,367
|
|
G |
ESRRA |
estrogen related receptor alpha |
increases expression |
EXP |
Carmustine results in increased expression of ESRRA mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:64,305,524...64,316,743
Ensembl chr11:64,305,497...64,316,743
|
|
G |
ETV1 |
ETS variant transcription factor 1 |
affects response to substance affects expression |
EXP ISO |
ETV1 mRNA affects the susceptibility to Carmustine Carmustine affects the expression of ETV1 mRNA |
CTD |
PMID:16365179 PMID:19174181 |
|
NCBI chr 7:13,891,229...13,991,425
Ensembl chr 7:13,891,229...13,991,425
|
|
G |
EXTL1 |
exostosin like glycosyltransferase 1 |
affects response to substance |
EXP |
EXTL1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:26,021,775...26,036,464
Ensembl chr 1:26,019,884...26,036,464
|
|
G |
EZH2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
decreases expression |
EXP |
Carmustine results in decreased expression of EZH2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 7:148,807,383...148,884,291
Ensembl chr 7:148,807,257...148,884,321
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
Carmustine results in increased expression of F3 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
G |
FANCC |
FA complementation group C |
affects response to substance |
EXP |
FANCC mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 9:95,099,054...95,317,709
Ensembl chr 9:95,099,054...95,426,796
|
|
G |
FANCD2 |
FA complementation group D2 |
increases ubiquitination affects localization |
EXP |
Carmustine results in increased ubiquitination of FANCD2 protein Carmustine affects the localization of FANCD2 protein |
CTD |
PMID:17221219 |
|
NCBI chr 3:10,026,437...10,101,932
Ensembl chr 3:10,026,370...10,101,932
|
|
G |
FBLN5 |
fibulin 5 |
decreases expression |
ISO |
Carmustine results in decreased expression of FBLN5 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr14:91,869,411...91,947,694
Ensembl chr14:91,869,411...91,947,987
|
|
G |
FBN1 |
fibrillin 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of FBN1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr15:48,408,313...48,645,709
Ensembl chr15:48,408,313...48,645,721
|
|
G |
FBXO32 |
F-box protein 32 |
affects response to substance |
EXP |
FBXO32 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 8:123,497,889...123,541,206
Ensembl chr 8:123,497,889...123,541,206
|
|
G |
FECH |
ferrochelatase |
multiple interactions |
EXP |
[MGMT protein mutant form co-treated with FECH protein] results in decreased susceptibility to [O(6)-benzylguanine co-treated with Carmustine] |
CTD |
PMID:12950064 |
|
NCBI chr18:57,544,377...57,586,702
Ensembl chr18:57,544,377...57,586,732
|
|
G |
FGF2 |
fibroblast growth factor 2 |
decreases response to substance |
EXP |
FGF2 protein results in decreased susceptibility to Carmustine |
CTD |
PMID:20221717 |
|
NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236
|
|
G |
FHL2 |
four and a half LIM domains 2 |
affects response to substance |
EXP |
FHL2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 2:105,357,712...105,438,529
Ensembl chr 2:105,357,712...105,438,513
|
|
G |
FKBP1A |
FKBP prolyl isomerase 1A |
decreases expression |
EXP |
Carmustine results in decreased expression of FKBP1A mRNA |
CTD |
PMID:15980968 |
|
NCBI chr20:1,368,978...1,393,054
Ensembl chr20:1,368,977...1,393,164
|
|
G |
FKBP5 |
FKBP prolyl isomerase 5 |
increases expression |
ISO |
Carmustine results in increased expression of FKBP5 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
|
|
G |
FNTA |
farnesyltransferase, CAAX box, subunit alpha |
decreases expression increases expression |
EXP |
Carmustine results in decreased expression of FNTA mRNA Carmustine results in increased expression of FNTA mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 8:43,056,323...43,085,785
Ensembl chr 8:43,034,194...43,085,788
|
|
G |
FOXF2 |
forkhead box F2 |
affects response to substance |
EXP |
FOXF2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 6:1,389,576...1,395,603
Ensembl chr 6:1,389,576...1,395,603
|
|
G |
FOXJ1 |
forkhead box J1 |
decreases expression |
EXP |
Carmustine results in decreased expression of FOXJ1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:76,136,333...76,141,245
Ensembl chr17:76,136,333...76,141,245
|
|
G |
FTH1 |
ferritin heavy chain 1 |
multiple interactions decreases response to substance decreases expression |
EXP |
Carmustine inhibits the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of FTH1 mRNA] FTH1 results in decreased susceptibility to Carmustine Carmustine results in decreased expression of FTH1 mRNA |
CTD |
PMID:15980968 PMID:16631525 PMID:21385903 |
|
NCBI chr11:61,964,285...61,967,634
Ensembl chr11:61,959,718...61,967,634
|
|
G |
FTL |
ferritin light chain |
decreases expression |
EXP |
Carmustine results in decreased expression of FTL mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:48,965,309...48,966,879
Ensembl chr19:48,965,309...48,967,896
|
|
G |
FUT8 |
fucosyltransferase 8 |
affects response to substance |
EXP |
FUT8 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr14:65,356,842...65,744,121
Ensembl chr14:65,410,592...65,744,121
|
|
G |
FYN |
FYN proto-oncogene, Src family tyrosine kinase |
decreases expression |
EXP |
Carmustine results in decreased expression of FYN mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 6:111,660,332...111,873,452
Ensembl chr 6:111,660,332...111,873,452
|
|
G |
GABRA2 |
gamma-aminobutyric acid type A receptor subunit alpha2 |
affects response to substance decreases expression |
EXP |
GABRA2 mRNA affects the susceptibility to Carmustine Carmustine results in decreased expression of GABRA2 mRNA |
CTD |
PMID:15980968 PMID:16365179 |
|
NCBI chr 4:46,243,548...46,390,300
Ensembl chr 4:46,243,548...46,475,230
|
|
G |
GABRA6 |
gamma-aminobutyric acid type A receptor subunit alpha6 |
decreases expression |
EXP |
Carmustine results in decreased expression of GABRA6 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 5:161,685,721...161,702,592
Ensembl chr 5:161,547,063...161,702,593
|
|
G |
GALNT15 |
polypeptide N-acetylgalactosaminyltransferase 15 |
affects response to substance |
EXP |
GALNT15 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 3:16,174,680...16,248,224
Ensembl chr 3:16,174,680...16,231,992
|
|
G |
GAMT |
guanidinoacetate N-methyltransferase |
decreases expression |
EXP |
Carmustine results in decreased expression of GAMT mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:1,397,026...1,401,542
Ensembl chr19:1,397,026...1,401,570
|
|
G |
GARNL3 |
GTPase activating Rap/RanGAP domain like 3 |
affects response to substance |
EXP |
GARNL3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 9:127,224,613...127,393,660
Ensembl chr 9:127,224,265...127,393,660
|
|
G |
GAST |
gastrin |
decreases expression |
EXP |
Carmustine results in decreased expression of GAST mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:41,712,331...41,715,969
Ensembl chr17:41,712,331...41,715,969
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Carmustine] results in decreased activity of GCLC protein; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of GCLC protein |
CTD |
PMID:12967637 PMID:16288907 |
|
NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
|
|
G |
GCM1 |
glial cells missing transcription factor 1 |
increases expression |
EXP |
Carmustine results in increased expression of GCM1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 6:53,126,961...53,148,841
Ensembl chr 6:53,126,961...53,148,841
|
|
G |
GDI1 |
GDP dissociation inhibitor 1 |
increases expression |
EXP |
Carmustine results in increased expression of GDI1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr X:154,437,154...154,443,467
Ensembl chr X:154,436,913...154,443,467
|
|
G |
GDI2 |
GDP dissociation inhibitor 2 |
increases expression |
EXP |
Carmustine results in increased expression of GDI2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr10:5,765,223...5,813,434
Ensembl chr10:5,765,222...5,842,132
|
|
G |
GDNF |
glial cell derived neurotrophic factor |
decreases response to substance |
EXP |
GDNF protein results in decreased susceptibility to Carmustine |
CTD |
PMID:19138852 |
|
NCBI chr 5:37,812,677...37,840,041
Ensembl chr 5:37,812,677...37,840,041
|
|
G |
GFAP |
glial fibrillary acidic protein |
decreases expression multiple interactions |
EXP ISO |
Carmustine results in decreased expression of GFAP mRNA Melatonin inhibits the reaction [Carmustine results in decreased expression of GFAP protein] |
CTD |
PMID:15980968 PMID:17572393 |
|
NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937
|
|
G |
GFOD3P |
Gfo/Idh/MocA-like oxidoreductase domain containing 3, pseudogene |
affects response to substance |
EXP |
GFOD3P mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:3,735,984...3,747,373
Ensembl chr 1:3,735,511...3,747,373 Ensembl chr 1:3,735,511...3,747,373
|
|
G |
GHSR |
growth hormone secretagogue receptor |
decreases expression |
EXP |
Carmustine results in decreased expression of GHSR mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 3:172,443,291...172,448,456
Ensembl chr 3:172,443,291...172,448,456
|
|
G |
GLRB |
glycine receptor beta |
affects response to substance |
EXP |
GLRB mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 4:157,076,150...157,172,090
Ensembl chr 4:157,076,125...157,172,090
|
|
G |
GNRHR |
gonadotropin releasing hormone receptor |
increases expression |
EXP |
Carmustine results in increased expression of GNRHR mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 4:67,737,118...67,754,388
Ensembl chr 4:67,737,118...67,754,388
|
|
G |
GOLGA2 |
golgin A2 |
decreases expression |
EXP |
Carmustine results in decreased expression of GOLGA2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 9:128,255,829...128,276,007
Ensembl chr 9:128,255,829...128,276,026
|
|
G |
GOLGA4 |
golgin A4 |
increases expression |
EXP |
Carmustine results in increased expression of GOLGA4 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 3:37,243,271...37,366,879
Ensembl chr 3:37,243,191...37,366,879
|
|
G |
GOLGA8B |
golgin A8 family member B |
affects response to substance |
EXP |
GOLGA8B mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr15:34,525,095...34,583,651
Ensembl chr15:34,525,095...34,588,503
|
|
G |
GP1BB |
glycoprotein Ib platelet subunit beta |
decreases expression |
EXP |
Carmustine results in decreased expression of GP1BB mRNA |
CTD |
PMID:15980968 |
|
NCBI chr22:19,723,539...19,724,771
Ensembl chr22:19,723,539...19,724,771
|
|
G |
GPR25 |
G protein-coupled receptor 25 |
decreases expression |
EXP |
Carmustine results in decreased expression of GPR25 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:200,872,981...200,874,178
Ensembl chr 1:200,872,981...200,874,178
|
|
G |
GPR32 |
G protein-coupled receptor 32 |
decreases expression |
EXP |
Carmustine results in decreased expression of GPR32 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:50,770,464...50,771,732
Ensembl chr19:50,770,464...50,771,732
|
|
G |
GPR37 |
G protein-coupled receptor 37 |
decreases expression |
EXP |
Carmustine results in decreased expression of GPR37 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 7:124,743,885...124,765,792
Ensembl chr 7:124,743,885...124,765,792
|
|
G |
GPR65 |
G protein-coupled receptor 65 |
increases expression |
EXP |
Carmustine results in increased expression of GPR65 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr14:88,005,135...88,014,811
Ensembl chr14:88,005,135...88,014,811
|
|
G |
GRB7 |
growth factor receptor bound protein 7 |
decreases expression |
EXP |
Carmustine results in decreased expression of GRB7 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:39,737,938...39,747,285
Ensembl chr17:39,737,927...39,747,291
|
|
G |
GRN |
granulin precursor |
decreases expression |
EXP |
Carmustine results in decreased expression of GRN mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:44,345,302...44,353,106
Ensembl chr17:44,345,246...44,353,106
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions decreases activity |
EXP ISO |
[Carmustine results in decreased activity of GSR protein] which results in increased susceptibility to Doxorubicin; [Carmustine results in decreased activity of GSR protein] which results in increased susceptibility to zinc chloride; Glutathione Disulfide inhibits the reaction [Carmustine results in decreased activity of GSR protein]; NADP affects the reaction [Carmustine results in decreased activity of GSR protein] [Buthionine Sulfoximine co-treated with Carmustine] results in decreased activity of GSR protein; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of GSR protein; [Carmustine results in decreased activity of GSR protein] which results in increased susceptibility to Streptozocin; [Carmustine results in decreased activity of GSR protein] which results in increased uptake of Calcium; MT2 protein inhibits the reaction [Carmustine results in decreased activity of GSR protein]; Zinc Sulfate inhibits the reaction [Carmustine results in decreased activity of GSR protein] [[Carmustine results in decreased activity of GSR protein] which co-treated with Oligodeoxyribonucleotides analog] results in increased abundance of Glutathione Disulfide; [[Cyclophosphamide co-treated with Cisplatin co-treated with Carmustine] results in decreased activity of GSR protein] which results in increased abundance of Glutathione Disulfide; [Carmustine results in decreased activity of GSR protein] which results in decreased susceptibility to chromium hexavalent ion; [Cyclophosphamide co-treated with Cisplatin co-treated with Carmustine] results in decreased activity of GSR protein |
CTD |
PMID:2116959 PMID:12114195 PMID:12433058 PMID:12477282 PMID:12632252 PMID:12967637 PMID:15104113 PMID:15321730 PMID:15720826 PMID:15857610 PMID:16160061 PMID:16288907 PMID:17382203 PMID:17498860 PMID:18155673 PMID:18528683 PMID:19401447 PMID:19668867 PMID:19856331 PMID:20046642 PMID:21600974 More...
|
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
GSTM1 |
glutathione S-transferase mu 1 |
affects response to substance decreases response to substance multiple interactions |
EXP |
GSTM1 gene affects the susceptibility to Carmustine GSTM1 protein results in decreased susceptibility to Carmustine GSTM1 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] |
CTD |
PMID:16087946 PMID:20067466 |
|
NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
|
|
G |
GSTM2 |
glutathione S-transferase mu 2 |
decreases nitrosation |
EXP |
GSTM2 protein results in decreased nitrosation of Carmustine |
CTD |
PMID:11841793 |
|
NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
|
|
G |
GSTM3 |
glutathione S-transferase mu 3 |
affects metabolic processing decreases nitrosation multiple interactions |
EXP |
GSTM3 protein affects the metabolism of Carmustine GSTM3 protein results in decreased nitrosation of Carmustine GSTM3 protein results in decreased nitrosation of and results in decreased activity of Carmustine |
CTD |
PMID:8395980 PMID:11841793 PMID:15247628 |
|
NCBI chr 1:109,733,937...109,741,038
Ensembl chr 1:109,733,932...109,741,038
|
|
G |
GSTP1 |
glutathione S-transferase pi 1 |
multiple interactions decreases response to substance |
EXP |
GSTP1 gene SNP results in increased susceptibility to [Carmustine co-treated with Doxorubicin co-treated with Cyclophosphamide co-treated with Melphalan] GSTP1 protein results in decreased susceptibility to Carmustine |
CTD |
PMID:12791655 PMID:16899598 |
|
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
|
|
G |
GSTT1 |
glutathione S-transferase theta 1 |
decreases nitrosation affects metabolic processing affects response to substance |
EXP ISO |
GSTT1 protein results in decreased nitrosation of Carmustine GSTT1 protein affects the metabolism of Carmustine GSTT1 protein affects the susceptibility to Carmustine |
CTD |
PMID:11841793 PMID:16874663 PMID:17827337 |
|
|
|
G |
GTF2F1 |
general transcription factor IIF subunit 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of GTF2F1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:6,379,572...6,393,164
Ensembl chr19:6,379,572...6,393,981
|
|
G |
GUCY1B2 |
guanylate cyclase 1 soluble subunit beta 2 (pseudogene) |
decreases expression |
ISO |
Carmustine results in decreased expression of GUCY1B2 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr13:50,994,511...51,066,157
Ensembl chr13:51,006,991...51,062,894 Ensembl chr13:51,006,991...51,062,894
|
|
G |
H2AX |
H2A.X variant histone |
decreases expression increases phosphorylation multiple interactions affects localization |
EXP |
Carmustine results in decreased expression of H2AX mRNA Carmustine results in increased phosphorylation of H2AX protein MDM4 protein promotes the reaction [Carmustine affects the localization of H2AX protein]; MDM4 protein promotes the reaction [Carmustine results in increased phosphorylation of H2AX protein] |
CTD |
PMID:15980968 PMID:20472715 |
|
NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465
|
|
G |
HACL1 |
2-hydroxyacyl-CoA lyase 1 |
decreases expression |
ISO |
Carmustine results in decreased expression of HACL1 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 3:15,560,699...15,601,569
Ensembl chr 3:15,560,699...15,601,852
|
|
G |
HADH |
hydroxyacyl-CoA dehydrogenase |
decreases expression |
EXP |
Carmustine results in decreased expression of HADH mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 4:107,989,889...108,035,171
Ensembl chr 4:107,989,714...108,035,241
|
|
G |
HAGH |
hydroxyacylglutathione hydrolase |
decreases expression |
EXP |
Carmustine results in decreased expression of HAGH mRNA |
CTD |
PMID:15980968 |
|
NCBI chr16:1,807,629...1,827,194
Ensembl chr16:1,795,620...1,827,157
|
|
G |
HCFC1 |
host cell factor C1 |
decreases expression |
EXP |
Carmustine results in decreased expression of HCFC1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr X:153,947,557...153,971,818
Ensembl chr X:153,947,557...153,971,818
|
|
G |
HHAT |
hedgehog acyltransferase |
affects response to substance |
EXP |
HHAT mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:210,327,328...210,676,290
Ensembl chr 1:210,328,252...210,676,296
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
decreases response to substance multiple interactions |
ISO |
HIF1A protein results in decreased susceptibility to Carmustine [cobaltous chloride results in increased activity of HIF1A protein] which results in decreased susceptibility to Carmustine; [Deferoxamine results in increased activity of HIF1A protein] which results in decreased susceptibility to Carmustine |
CTD |
PMID:14980978 PMID:15965067 |
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HMGN2 |
high mobility group nucleosomal binding domain 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of HMGN2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:26,472,440...26,476,642
Ensembl chr 1:26,472,440...26,478,209
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Carmustine inhibits the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of HMOX1 mRNA] |
CTD |
PMID:16631525 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HNF1A |
HNF1 homeobox A |
decreases expression |
EXP |
Carmustine results in decreased expression of HNF1A mRNA |
CTD |
PMID:15980968 |
|
NCBI chr12:120,978,543...121,002,512
Ensembl chr12:120,978,543...121,002,512
|
|
G |
HOXA4 |
homeobox A4 |
decreases expression |
EXP |
Carmustine results in decreased expression of HOXA4 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 7:27,128,525...27,130,757
Ensembl chr 7:27,128,507...27,130,780
|
|
G |
HPRT1 |
hypoxanthine phosphoribosyltransferase 1 |
increases mutagenesis |
ISO |
Carmustine results in increased mutagenesis of HPRT1 gene |
CTD |
PMID:17116724 |
|
NCBI chr X:134,460,165...134,500,668
Ensembl chr X:134,460,165...134,520,513
|
|
G |
ICAM5 |
intercellular adhesion molecule 5 |
decreases expression |
EXP |
Carmustine results in decreased expression of ICAM5 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:10,289,952...10,296,778
Ensembl chr19:10,289,952...10,296,778
|
|
G |
IDS |
iduronate 2-sulfatase |
decreases expression |
EXP |
Carmustine results in decreased expression of IDS mRNA |
CTD |
PMID:15980968 |
|
NCBI chr X:149,476,988...149,505,306
Ensembl chr X:149,476,988...149,521,096
|
|
G |
IER3 |
immediate early response 3 |
decreases expression |
EXP |
Carmustine results in decreased expression of IER3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 6:30,743,199...30,744,547
Ensembl chr 6:30,743,199...30,744,548
|
|
G |
IFIT1 |
interferon induced protein with tetratricopeptide repeats 1 |
affects response to substance |
EXP |
IFIT1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr10:89,392,623...89,406,487
Ensembl chr10:89,392,546...89,406,487
|
|
G |
IGF1 |
insulin like growth factor 1 |
decreases expression increases expression |
EXP |
Carmustine results in decreased expression of IGF1 protein Carmustine results in increased expression of IGF1 protein |
CTD |
PMID:15286697 PMID:18443378 |
|
NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744
|
|
G |
IGF2 |
insulin like growth factor 2 |
affects response to substance |
EXP |
IGF2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr11:2,129,117...2,149,566
Ensembl chr11:2,129,112...2,158,391
|
|
G |
IGFBP3 |
insulin like growth factor binding protein 3 |
decreases expression |
ISO |
Carmustine results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 7:45,912,245...45,921,272
Ensembl chr 7:45,912,245...45,921,874
|
|
G |
IKBKG |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
decreases expression |
EXP |
Carmustine results in decreased expression of IKBKG mRNA |
CTD |
PMID:15980968 |
|
NCBI chr X:154,541,238...154,565,046
Ensembl chr X:154,541,199...154,565,046
|
|
G |
IL12B |
interleukin 12B |
multiple interactions |
ISO |
Carmustine promotes the reaction [Lipopolysaccharides results in increased expression of IL12B protein] |
CTD |
PMID:12688424 |
|
NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
Carmustine promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:11970852 PMID:12433058 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL1R1 |
interleukin 1 receptor type 1 |
affects response to substance |
EXP |
IL1R1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 2:102,070,390...102,179,874
Ensembl chr 2:102,064,544...102,179,874
|
|
G |
IL6 |
interleukin 6 |
affects response to substance multiple interactions |
EXP ISO |
IL6 mRNA affects the susceptibility to Carmustine Carmustine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Carmustine promotes the reaction [Oligodeoxyribonucleotides analog results in increased secretion of IL6 protein] |
CTD |
PMID:11970852 PMID:12433058 PMID:12477282 PMID:16365179 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INHBA |
inhibin subunit beta A |
affects response to substance |
EXP |
INHBA mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 7:41,685,114...41,705,406
Ensembl chr 7:41,667,168...41,705,834
|
|
G |
INPPL1 |
inositol polyphosphate phosphatase like 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of INPPL1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:72,223,563...72,239,147
Ensembl chr11:72,223,701...72,239,147
|
|
G |
INSIG1 |
insulin induced gene 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of INSIG1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235
|
|
G |
INSL3 |
insulin like 3 |
decreases expression |
EXP |
Carmustine results in decreased expression of INSL3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:17,816,512...17,821,519
Ensembl chr19:17,816,512...17,821,574
|
|
G |
IPO4 |
importin 4 |
affects response to substance |
EXP |
IPO4 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr14:24,180,219...24,188,816
Ensembl chr14:24,180,219...24,188,869
|
|
G |
IRAG2 |
inositol 1,4,5-triphosphate receptor associated 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of IRAG2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr12:24,997,575...25,108,335
Ensembl chr12:25,004,342...25,108,335
|
|
G |
IRS1 |
insulin receptor substrate 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of IRS1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 2:226,731,312...226,799,820
Ensembl chr 2:226,731,312...226,799,820
|
|
G |
ISLR |
immunoglobulin superfamily containing leucine rich repeat |
decreases expression |
EXP ISO |
Carmustine results in decreased expression of ISLR mRNA |
CTD |
PMID:15980968 PMID:16005536 |
|
NCBI chr15:74,173,710...74,176,871
Ensembl chr15:74,173,710...74,176,872
|
|
G |
ITGA3 |
integrin subunit alpha 3 |
decreases expression |
EXP |
Carmustine results in decreased expression of ITGA3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:50,056,110...50,090,481
Ensembl chr17:50,055,968...50,090,481
|
|
G |
ITGB1 |
integrin subunit beta 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of ITGB1 protein |
CTD |
PMID:18443378 |
|
NCBI chr10:32,900,318...32,958,230
Ensembl chr10:32,887,273...33,005,792
|
|
G |
ITGB3 |
integrin subunit beta 3 |
increases response to substance multiple interactions |
EXP ISO |
ITGB3 protein results in increased susceptibility to Carmustine 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [ITGB3 protein results in increased susceptibility to Carmustine] |
CTD |
PMID:21332719 |
|
NCBI chr17:47,253,827...47,313,743
Ensembl chr17:47,253,827...47,313,743
|
|
G |
ITIH1 |
inter-alpha-trypsin inhibitor heavy chain 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of ITIH1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 3:52,777,599...52,792,068
Ensembl chr 3:52,777,595...52,792,068
|
|
G |
KCNA4 |
potassium voltage-gated channel subfamily A member 4 |
multiple interactions |
ISO |
[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCNA4 protein |
CTD |
PMID:16288907 |
|
NCBI chr11:30,009,730...30,017,030
Ensembl chr11:30,009,730...30,017,030
|
|
G |
KCNAB2 |
potassium voltage-gated channel subfamily A regulatory beta subunit 2 |
affects response to substance |
EXP |
KCNAB2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:5,992,676...6,101,180
Ensembl chr 1:5,990,927...6,101,193
|
|
G |
KCND2 |
potassium voltage-gated channel subfamily D member 2 |
multiple interactions |
ISO |
[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 mRNA; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 protein |
CTD |
PMID:16288907 |
|
NCBI chr 7:120,272,908...120,750,337
Ensembl chr 7:120,273,175...120,750,337
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of KCNH2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
KIF2C |
kinesin family member 2C |
decreases expression |
ISO |
Carmustine results in decreased expression of KIF2C mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 1:44,739,837...44,767,767
Ensembl chr 1:44,739,818...44,767,767
|
|
G |
KIF5A |
kinesin family member 5A |
decreases expression |
EXP |
Carmustine results in decreased expression of KIF5A mRNA |
CTD |
PMID:15980968 |
|
NCBI chr12:57,550,044...57,586,633
Ensembl chr12:57,546,026...57,586,633
|
|
G |
KRT17 |
keratin 17 |
decreases expression |
EXP |
Carmustine results in decreased expression of KRT17 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:41,619,442...41,624,575
Ensembl chr17:41,619,442...41,624,842
|
|
G |
KRT31 |
keratin 31 |
decreases expression |
EXP |
Carmustine results in decreased expression of KRT31 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:41,393,721...41,397,608
Ensembl chr17:41,393,721...41,397,608
|
|
G |
KRT8 |
keratin 8 |
affects response to substance |
EXP |
KRT8 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr12:52,897,191...52,949,860
Ensembl chr12:52,897,187...52,949,954
|
|
G |
LAD1 |
ladinin 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of LAD1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:201,380,833...201,399,324
Ensembl chr 1:201,380,833...201,399,915
|
|
G |
LAIR1 |
leukocyte associated immunoglobulin like receptor 1 |
increases expression |
EXP |
Carmustine results in increased expression of LAIR1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:54,351,384...54,376,088
Ensembl chr19:54,351,384...54,370,558
|
|
G |
LAMB3 |
laminin subunit beta 3 |
decreases expression |
EXP |
Carmustine results in decreased expression of LAMB3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:209,614,870...209,652,425
Ensembl chr 1:209,614,870...209,652,425
|
|
G |
LBP |
lipopolysaccharide binding protein |
affects response to substance |
EXP |
LBP mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr20:38,346,482...38,377,013
Ensembl chr20:38,346,482...38,377,013
|
|
G |
LCN2 |
lipocalin 2 |
increases response to substance multiple interactions |
EXP ISO |
LCN2 protein results in increased susceptibility to Carmustine [LCN2 protein co-treated with Carmustine] results in increased cleavage of and results in increased activity of CASP3 protein; LCN2 protein promotes the reaction [Carmustine results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:19860839 |
|
NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453
|
|
G |
LDLR |
low density lipoprotein receptor |
affects uptake |
EXP |
LDLR protein affects the uptake of Carmustine analog |
CTD |
PMID:12107554 |
|
NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820
|
|
G |
LIF |
LIF interleukin 6 family cytokine |
increases response to substance |
EXP |
LIF mRNA results in increased susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr22:30,240,453...30,246,759
Ensembl chr22:30,240,453...30,246,759
|
|
G |
LIG1 |
DNA ligase 1 |
decreases expression |
ISO |
Carmustine results in decreased expression of LIG1 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr19:48,115,445...48,170,344
Ensembl chr19:48,115,445...48,170,603
|
|
G |
LINS1 |
lines homolog 1 |
affects response to substance |
EXP |
LINS1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr15:100,566,924...100,602,184
Ensembl chr15:100,559,369...100,603,230
|
|
G |
LMAN1L |
lectin, mannose binding 1 like |
affects response to substance |
EXP |
LMAN1L mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr15:74,812,835...74,825,754
Ensembl chr15:74,812,716...74,825,757
|
|
G |
LMTK2 |
lemur tyrosine kinase 2 |
affects response to substance |
EXP |
LMTK2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 7:98,106,862...98,209,638
Ensembl chr 7:98,106,862...98,209,638
|
|
G |
LMX1B |
LIM homeobox transcription factor 1 beta |
decreases expression |
EXP |
Carmustine results in decreased expression of LMX1B mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 9:126,613,928...126,701,032
Ensembl chr 9:126,613,928...126,701,032
|
|
G |
LOXL1 |
lysyl oxidase like 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of LOXL1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr15:73,926,462...73,952,136
Ensembl chr15:73,925,989...73,952,137
|
|
G |
LRCH4 |
leucine rich repeats and calponin homology domain containing 4 |
decreases expression |
EXP |
Carmustine results in decreased expression of LRCH4 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 7:100,574,011...100,586,129
Ensembl chr 7:100,574,011...100,586,129
|
|
G |
LSP1 |
lymphocyte specific protein 1 |
decreases expression |
ISO |
Carmustine results in decreased expression of LSP1 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr11:1,853,084...1,892,263
Ensembl chr11:1,850,904...1,892,267
|
|
G |
MAD1L1 |
mitotic arrest deficient 1 like 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of MAD1L1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 7:1,815,795...2,232,945
Ensembl chr 7:1,815,793...2,233,243
|
|
G |
MALAT1 |
metastasis associated lung adenocarcinoma transcript 1 |
affects response to substance |
EXP |
MALAT1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr11:65,497,738...65,506,516
Ensembl chr11:65,497,606...65,508,073
|
|
G |
MAP4K2 |
mitogen-activated protein kinase kinase kinase kinase 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of MAP4K2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:64,784,918...64,803,214
Ensembl chr11:64,784,918...64,803,241
|
|
G |
MAPK10 |
mitogen-activated protein kinase 10 |
decreases expression |
EXP |
Carmustine results in decreased expression of MAPK10 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 4:86,010,405...86,594,074
Ensembl chr 4:85,990,007...86,594,625
|
|
G |
MASP1 |
MBL associated serine protease 1 |
affects response to substance |
EXP |
MASP1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 3:187,217,282...187,291,737
Ensembl chr 3:187,217,282...187,291,980
|
|
G |
MAT1A |
methionine adenosyltransferase 1A |
decreases expression |
EXP |
Carmustine results in decreased expression of MAT1A mRNA |
CTD |
PMID:15980968 |
|
NCBI chr10:80,271,820...80,289,658
Ensembl chr10:80,271,820...80,289,658
|
|
G |
MDK |
midkine |
decreases expression |
EXP |
Carmustine results in decreased expression of MDK mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:46,380,784...46,383,837
Ensembl chr11:46,380,756...46,383,837
|
|
G |
MDM4 |
MDM4 regulator of p53 |
multiple interactions decreases response to substance |
EXP |
[Carmustine co-treated with MDM4 protein] results in increased expression of POLH protein; MDM4 protein promotes the reaction [Carmustine affects the localization of H2AX protein]; MDM4 protein promotes the reaction [Carmustine results in increased expression of CDKN1A protein]; MDM4 protein promotes the reaction [Carmustine results in increased expression of TP53 protein]; MDM4 protein promotes the reaction [Carmustine results in increased phosphorylation of H2AX protein] MDM4 protein results in decreased susceptibility to Carmustine |
CTD |
PMID:20472715 |
|
NCBI chr 1:204,516,406...204,558,120
Ensembl chr 1:204,516,379...204,558,120
|
|
G |
MECOM |
MDS1 and EVI1 complex locus |
affects response to substance |
EXP |
MECOM mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 3:169,083,507...169,663,712
Ensembl chr 3:169,083,499...169,663,775
|
|
G |
MED1 |
mediator complex subunit 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of MED1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:39,404,285...39,451,263
Ensembl chr17:39,404,285...39,451,272
|
|
G |
MEG3 |
maternally expressed 3 |
affects response to substance |
EXP |
MEG3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr14:100,826,108...100,861,026
Ensembl chr14:100,779,206...100,861,031
|
|
G |
MGAT3 |
beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase |
decreases expression |
EXP |
Carmustine results in decreased expression of MGAT3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr22:39,457,012...39,492,194
Ensembl chr22:39,457,012...39,492,194
|
|
G |
MGMT |
O-6-methylguanine-DNA methyltransferase |
increases alkylation increases response to substance multiple interactions decreases expression decreases response to substance affects response to substance decreases activity |
EXP ISO |
Carmustine results in increased alkylation of MGMT protein MGMT mutant form results in increased susceptibility to Carmustine [MGMT protein co-treated with ABCB1 protein] results in decreased susceptibility to Carmustine; [MGMT protein mutant form co-treated with FECH protein] results in decreased susceptibility to [O(6)-benzylguanine co-treated with Carmustine]; [O(6)-benzyl-2'-deoxyguanosine results in decreased activity of MGMT protein] which results in increased susceptibility to Carmustine; [O(6)-benzyl-N-acetylguanosine results in decreased activity of MGMT protein] which results in increased susceptibility to Carmustine; [O(6)-benzylguanine co-treated with Carmustine] results in decreased activity of MGMT protein; [O(6)-benzylguanine results in decreased activity of MGMT protein] which results in increased susceptibility to Carmustine; [Tamoxifen results in increased degradation of MGMT protein] which results in increased susceptibility to Carmustine; MGMT protein mutant form results in decreased susceptibility to [Carmustine co-treated with O(6)-benzylguanine]; MGMT protein mutant form results in decreased susceptibility to [O(6)-benzylguanine co-treated with Carmustine]; MGMT protein results in decreased susceptibility to [Carmustine co-treated with O(6)-benzylguanine]; MGMT protein results in decreased susceptibility to [O(6)-benzylguanine co-treated with Carmustine]; O(6)-benzylguanine inhibits the reaction [MGMT protein mutant form results in decreased susceptibility to Carmustine] Carmustine results in decreased expression of MGMT protein MGMT protein results in decreased susceptibility to Carmustine [O(6)-benzylguanine results in decreased activity of MGMT protein] which affects the susceptibility to Carmustine; MGMT protein mutant form results in decreased susceptibility to [Carmustine co-treated with O(6)-benzylguanine]; MGMT protein results in decreased susceptibility to [Carmustine co-treated with O(6)-benzylguanine] MGMT protein affects the susceptibility to Carmustine Carmustine results in decreased activity of MGMT protein MGMT mRNA results in decreased susceptibility to Carmustine; MGMT protein mutant form results in decreased susceptibility to Carmustine; MGMT protein results in decreased susceptibility to Carmustine; MGMT protein results in decreased susceptibility to Carmustine analog; MGMT results in decreased susceptibility to Carmustine MGMT gene modified form affects the susceptibility to Carmustine; MGMT promoter modified form affects the susceptibility to Carmustine; MGMT protein affects the susceptibility to Carmustine |
CTD |
PMID:8823159 PMID:9918549 PMID:11792417 PMID:11945064 PMID:12036916 PMID:12394182 PMID:12479369 PMID:12684420 PMID:12950064 PMID:14506174 PMID:14617757 PMID:14670122 PMID:14707273 PMID:14742745 PMID:15104113 PMID:15284838 PMID:15319033 PMID:15814657 PMID:15833865 PMID:16033832 PMID:16039682 PMID:16126841 PMID:16278409 PMID:16365179 PMID:16405512 PMID:16432170 PMID:16899598 PMID:16927363 PMID:17597106 PMID:18430789 PMID:18492797 PMID:19415780 PMID:19637364 PMID:19844954 PMID:20450874 PMID:20556481 PMID:20654586 PMID:26208482 More...
|
|
NCBI chr10:129,467,241...129,770,983
Ensembl chr10:129,467,190...129,770,983
|
|
G |
MGST2 |
microsomal glutathione S-transferase 2 |
affects response to substance |
EXP |
MGST2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 4:139,665,819...139,754,618
Ensembl chr 4:139,665,768...139,740,745
|
|
G |
MLH1 |
mutL homolog 1 |
affects response to substance |
EXP |
MLH1 protein affects the susceptibility to Carmustine |
CTD |
PMID:18430789 |
|
NCBI chr 3:36,993,466...37,050,846
Ensembl chr 3:36,993,226...37,050,896
|
|
G |
MLPH |
melanophilin |
affects response to substance |
EXP |
MLPH mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 2:237,486,410...237,555,322
Ensembl chr 2:237,485,428...237,555,322
|
|
G |
MPG |
N-methylpurine DNA glycosylase |
decreases response to substance |
EXP |
MPG protein results in decreased susceptibility to Carmustine |
CTD |
PMID:16288039 |
|
NCBI chr16:77,007...85,846
Ensembl chr16:77,007...85,851
|
|
G |
MPST |
mercaptopyruvate sulfurtransferase |
affects response to substance |
EXP |
MPST mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr22:37,019,742...37,029,815
Ensembl chr22:37,019,635...37,029,821
|
|
G |
MSH2 |
mutS homolog 2 |
affects response to substance |
EXP |
MSH2 protein affects the susceptibility to Carmustine |
CTD |
PMID:18430789 |
|
NCBI chr 2:47,403,067...47,709,830
Ensembl chr 2:47,403,067...47,663,146
|
|
G |
MSR1 |
macrophage scavenger receptor 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of MSR1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 8:16,107,881...16,192,651
Ensembl chr 8:16,107,878...16,567,490
|
|
G |
MT1F |
metallothionein 1F |
affects response to substance |
EXP |
MT1F mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr16:56,657,959...56,659,303
Ensembl chr16:56,657,731...56,660,698
|
|
G |
MT1X |
metallothionein 1X |
affects response to substance |
EXP |
MT1X mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr16:56,682,470...56,684,196
Ensembl chr16:56,682,470...56,684,196
|
|
G |
MT2A |
metallothionein 2A |
affects response to substance multiple interactions |
EXP ISO |
MT2A mRNA affects the susceptibility to Carmustine MT2 protein inhibits the reaction [Carmustine results in decreased activity of GSR protein]; MT2 protein inhibits the reaction [Carmustine results in increased expression of TNF protein] MT2 protein affects the susceptibility to Carmustine |
CTD |
PMID:16365179 PMID:18528683 |
|
NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497
|
|
G |
MTURN |
maturin, neural progenitor differentiation regulator homolog |
affects response to substance |
EXP |
MTURN mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 7:30,134,986...30,162,762
Ensembl chr 7:30,134,986...30,162,765
|
|
G |
MUC2 |
mucin 2, oligomeric mucus/gel-forming |
decreases expression |
EXP |
Carmustine results in decreased expression of MUC2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:1,074,874...1,110,508
Ensembl chr11:1,074,875...1,110,511
|
|
G |
MVD |
mevalonate diphosphate decarboxylase |
decreases expression |
EXP |
Carmustine results in decreased expression of MVD mRNA |
CTD |
PMID:15980968 |
|
NCBI chr16:88,651,940...88,663,091
Ensembl chr16:88,651,935...88,663,161
|
|
G |
MYBL2 |
MYB proto-oncogene like 2 |
increases expression |
ISO |
Carmustine results in increased expression of MYBL2 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr20:43,667,114...43,716,482
Ensembl chr20:43,667,019...43,716,495
|
|
G |
MYBPH |
myosin binding protein H |
decreases expression |
EXP |
Carmustine results in decreased expression of MYBPH mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:203,167,811...203,179,214
Ensembl chr 1:203,167,811...203,175,826
|
|
G |
MYD88 |
MYD88 innate immune signal transduction adaptor |
decreases expression |
EXP |
Carmustine results in decreased expression of MYD88 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 3:38,138,661...38,143,022
Ensembl chr 3:38,138,552...38,143,024
|
|
G |
MYOD1 |
myogenic differentiation 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of MYOD1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:17,719,571...17,722,136
Ensembl chr11:17,719,571...17,722,136
|
|
G |
MYOG |
myogenin |
decreases expression |
EXP |
Carmustine results in decreased expression of MYOG mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:203,083,129...203,086,012
Ensembl chr 1:203,083,129...203,086,012
|
|
G |
NBL1 |
NBL1, DAN family BMP antagonist |
affects response to substance |
EXP |
NBL1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:19,643,229...19,658,452
Ensembl chr 1:19,596,979...19,658,456
|
|
G |
NDUFC1 |
NADH:ubiquinone oxidoreductase subunit C1 |
decreases expression |
EXP |
Carmustine results in decreased expression of NDUFC1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 4:139,289,917...139,302,551
Ensembl chr 4:139,266,880...139,302,551
|
|
G |
NEK6 |
NIMA related kinase 6 |
increases expression |
ISO |
Carmustine results in increased expression of NEK6 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 9:124,257,606...124,353,307
Ensembl chr 9:124,257,606...124,353,307
|
|
G |
NES |
nestin |
increases expression multiple interactions |
ISO |
Carmustine results in increased expression of NES protein Melatonin inhibits the reaction [Carmustine results in increased expression of NES protein] |
CTD |
PMID:17572393 |
|
NCBI chr 1:156,668,763...156,677,407
Ensembl chr 1:156,668,763...156,677,407
|
|
G |
NFAT5 |
nuclear factor of activated T cells 5 |
affects response to substance |
EXP |
NFAT5 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr16:69,565,966...69,704,654
Ensembl chr16:69,565,094...69,704,666
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
affects response to substance |
ISO |
[NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to Carmustine |
CTD |
PMID:19303893 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NFIB |
nuclear factor I B |
affects response to substance |
EXP |
NFIB mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 9:14,081,843...14,532,077
Ensembl chr 9:14,081,843...14,398,983
|
|
G |
NFIX |
nuclear factor I X |
affects response to substance |
EXP |
NFIX mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr19:12,995,475...13,098,796
Ensembl chr19:12,995,475...13,098,796
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP ISO |
Carmustine results in increased activity of [NFKB1 protein binds to NFKB1 protein]; Carmustine results in increased activity of [NFKB1 protein binds to RELA protein]; NFKBIA gene mutant form inhibits the reaction [Carmustine results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; NFKBIA gene mutant form inhibits the reaction [Carmustine results in increased activity of [NFKB1 protein binds to RELA protein]] Carmustine inhibits the reaction [Lipopolysaccharides affects the localization of NFKB1 protein]; Carmustine inhibits the reaction [Lipopolysaccharides results in increased activity of [NFKB1 protein binds to RELA protein]] [Carmustine co-treated with Oligodeoxyribonucleotides analog] results in increased activity of [NFKB1 protein binds to NFKB1 protein]; [Carmustine co-treated with Oligodeoxyribonucleotides analog] results in increased activity of [NFKB1 protein binds to RELA protein]; diphenyleneiodonium inhibits the reaction [[Carmustine co-treated with Oligodeoxyribonucleotides analog] results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; diphenyleneiodonium inhibits the reaction [[Carmustine co-treated with Oligodeoxyribonucleotides analog] results in increased activity of [NFKB1 protein binds to RELA protein]] |
CTD |
PMID:11970852 PMID:12433058 PMID:12477282 PMID:12675310 |
|
NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions increases response to substance |
EXP ISO |
NFKBIA gene mutant form inhibits the reaction [Carmustine results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; NFKBIA gene mutant form inhibits the reaction [Carmustine results in increased activity of [NFKB1 protein binds to RELA protein]] Carmustine inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; Carmustine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] NFKBIA gene mutant form results in increased susceptibility to Carmustine; NFKBIA mRNA results in increased susceptibility to Carmustine |
CTD |
PMID:11970852 PMID:12433058 PMID:12675310 PMID:16365179 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749
|
|
G |
NGEF |
neuronal guanine nucleotide exchange factor |
decreases expression |
ISO |
Carmustine results in decreased expression of NGEF mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 2:232,878,701...233,013,256
Ensembl chr 2:232,878,701...233,013,256
|
|
G |
NGF |
nerve growth factor |
affects activity |
ISO |
Carmustine affects the activity of NGF protein |
CTD |
PMID:15935206 |
|
NCBI chr 1:115,285,917...115,338,249
Ensembl chr 1:115,285,904...115,338,770
|
|
G |
NID2 |
nidogen 2 |
decreases expression |
ISO |
Carmustine results in decreased expression of NID2 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr14:52,004,809...52,069,059
Ensembl chr14:52,004,809...52,069,059
|
|
G |
NIN |
ninein |
affects response to substance |
EXP |
NIN mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr14:50,719,763...50,831,503
Ensembl chr14:50,719,763...50,831,162
|
|
G |
NKD2 |
NKD inhibitor of WNT signaling pathway 2 |
affects response to substance |
EXP |
NKD2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 5:1,008,802...1,038,943
Ensembl chr 5:1,008,802...1,038,943
|
|
G |
NKX2-2 |
NK2 homeobox 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of NKX2-2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr20:21,511,017...21,522,689
Ensembl chr20:21,511,017...21,514,064
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions decreases response to substance |
EXP ISO |
[NOS2 protein results in increased chemical synthesis of S-Nitrosoglutathione] which results in decreased susceptibility to Carmustine NOS2 protein results in decreased susceptibility to Carmustine [Carmustine co-treated with 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid] inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitrites]; [Carmustine co-treated with Buthionine Sulfoximine] inhibits the reaction [TNF protein results in increased expression of NOS2 protein]; Buthionine Sulfoximine promotes the reaction [Carmustine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]]; Carmustine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Carmustine] |
CTD |
PMID:7532384 PMID:15110396 PMID:15965067 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOTCH2NLA |
notch 2 N-terminal like A |
affects response to substance |
EXP |
NOTCH2NLA mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:146,148,865...146,229,021
Ensembl chr 1:146,146,203...146,229,041
|
|
G |
NPAS1 |
neuronal PAS domain protein 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of NPAS1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:47,019,837...47,045,775
Ensembl chr19:47,019,837...47,045,775
|
|
G |
NPAS2 |
neuronal PAS domain protein 2 |
affects response to substance |
EXP |
NPAS2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 2:100,818,723...100,996,829
Ensembl chr 2:100,820,139...100,996,829
|
|
G |
NPBWR2 |
neuropeptides B and W receptor 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of NPBWR2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr20:64,103,802...64,107,565
Ensembl chr20:64,103,802...64,107,565
|
|
G |
NPL |
N-acetylneuraminate pyruvate lyase |
affects response to substance |
EXP |
NPL mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:182,789,773...182,830,384
Ensembl chr 1:182,789,293...182,830,384
|
|
G |
NPR1 |
natriuretic peptide receptor 1 |
decreases expression |
ISO |
Carmustine results in decreased expression of NPR1 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 1:153,678,688...153,693,992
Ensembl chr 1:153,678,688...153,693,992
|
|
G |
NR2F1 |
nuclear receptor subfamily 2 group F member 1 |
affects response to substance |
EXP |
NR2F1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 5:93,583,222...93,594,611
Ensembl chr 5:93,583,222...93,594,611
|
|
G |
NR4A2 |
nuclear receptor subfamily 4 group A member 2 |
affects expression |
ISO |
Carmustine affects the expression of NR4A2 mRNA |
CTD |
PMID:19174181 |
|
NCBI chr 2:156,324,437...156,332,721
Ensembl chr 2:156,324,437...156,342,348
|
|
G |
NRTN |
neurturin |
decreases expression |
EXP |
Carmustine results in decreased expression of NRTN mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:5,805,067...5,828,324
Ensembl chr19:5,805,067...5,828,324
|
|
G |
OGG1 |
8-oxoguanine DNA glycosylase |
decreases response to substance |
EXP |
OGG1 protein results in decreased susceptibility to Carmustine |
CTD |
PMID:11181913 PMID:11741815 |
|
NCBI chr 3:9,749,952...9,783,108
Ensembl chr 3:9,749,944...9,788,219
|
|
G |
OMP |
olfactory marker protein |
decreases expression |
EXP |
Carmustine results in decreased expression of OMP mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:77,102,840...77,103,331
Ensembl chr11:77,102,840...77,103,331
|
|
G |
ORM1 |
orosomucoid 1 |
increases expression |
ISO |
Carmustine results in increased expression of ORM1 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 9:114,323,098...114,326,479
Ensembl chr 9:114,323,098...114,326,479
|
|
G |
P3H3 |
prolyl 3-hydroxylase 3 |
affects response to substance |
EXP |
P3H3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr12:6,828,407...6,839,847
Ensembl chr12:6,828,407...6,839,847
|
|
G |
PAEP |
progestagen associated endometrial protein |
decreases expression |
EXP |
Carmustine results in decreased expression of PAEP mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 9:135,561,756...135,566,955
Ensembl chr 9:135,561,756...135,566,955
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
EXP |
Disulfiram promotes the reaction [Carmustine results in increased cleavage of PARP1 protein] |
CTD |
PMID:24193513 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PAX8 |
paired box 8 |
decreases expression |
EXP |
Carmustine results in decreased expression of PAX8 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 2:113,215,997...113,278,921
Ensembl chr 2:113,215,997...113,278,921
|
|
G |
PBX2 |
PBX homeobox 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of PBX2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 6:32,184,733...32,190,202
Ensembl chr 6:32,184,733...32,190,202
|
|
G |
PCBD1 |
pterin-4 alpha-carbinolamine dehydratase 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of PCBD1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr10:70,882,280...70,888,565
Ensembl chr10:70,882,280...70,888,565
|
|
G |
PCDHB2 |
protocadherin beta 2 |
affects response to substance |
EXP |
PCDHB2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 5:141,094,615...141,098,703
Ensembl chr 5:141,094,606...141,098,703
|
|
G |
PCDHGC3 |
protocadherin gamma subfamily C, 3 |
decreases expression |
EXP |
Carmustine results in decreased expression of PCDHGC3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 5:141,475,966...141,512,975
Ensembl chr 5:141,475,947...141,512,977
|
|
G |
PCOLCE |
procollagen C-endopeptidase enhancer |
decreases expression |
EXP |
Carmustine results in decreased expression of PCOLCE mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 7:100,602,363...100,608,175
Ensembl chr 7:100,602,363...100,608,175
|
|
G |
PCYT1A |
phosphate cytidylyltransferase 1A, choline |
decreases expression |
EXP |
Carmustine results in decreased expression of PCYT1A mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 3:196,234,368...196,287,726
Ensembl chr 3:196,214,222...196,287,957
|
|
G |
PDE5A |
phosphodiesterase 5A |
affects response to substance |
EXP |
PDE5A mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 4:119,494,403...119,628,804
Ensembl chr 4:119,494,397...119,628,804
|
|
G |
PDGFB |
platelet derived growth factor subunit B |
increases expression |
EXP |
Carmustine results in increased expression of PDGFB protein |
CTD |
PMID:15286697 |
|
NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982
|
|
G |
PFKFB2 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of PFKFB2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:207,034,416...207,081,027
Ensembl chr 1:207,034,366...207,081,024
|
|
G |
PFKM |
phosphofructokinase, muscle |
decreases expression |
EXP |
Carmustine results in decreased expression of PFKM mRNA |
CTD |
PMID:15980968 |
|
NCBI chr12:48,105,353...48,146,404
Ensembl chr12:48,105,139...48,146,404
|
|
G |
PFN1 |
profilin 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of PFN1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:4,945,652...4,948,530
Ensembl chr17:4,945,652...4,949,061
|
|
G |
PGM2 |
phosphoglucomutase 2 |
affects response to substance |
EXP |
PGM2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 4:37,826,686...37,862,937
Ensembl chr 4:37,826,660...37,862,937
|
|
G |
PHC2 |
polyhomeotic homolog 2 |
affects response to substance |
EXP |
PHC2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:33,323,626...33,431,095
Ensembl chr 1:33,323,623...33,431,095
|
|
G |
PHLDA1 |
pleckstrin homology like domain family A member 1 |
affects response to substance |
EXP |
PHLDA1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr12:76,025,447...76,031,776
Ensembl chr12:76,025,447...76,031,776
|
|
G |
PIK3C3 |
phosphatidylinositol 3-kinase catalytic subunit type 3 |
affects response to substance |
EXP |
PIK3C3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr18:41,955,234...42,087,830
Ensembl chr18:41,955,234...42,087,830
|
|
G |
PIK3CD |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
affects response to substance |
EXP |
PIK3CD mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:9,627,258...9,729,114
Ensembl chr 1:9,629,889...9,729,114
|
|
G |
PIK3R3 |
phosphoinositide-3-kinase regulatory subunit 3 |
increases expression |
EXP |
Carmustine results in increased expression of PIK3R3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:46,040,140...46,174,901
Ensembl chr 1:46,040,140...46,133,036
|
|
G |
PITPNC1 |
phosphatidylinositol transfer protein cytoplasmic 1 |
affects response to substance |
EXP |
PITPNC1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr17:67,377,281...67,697,256
Ensembl chr17:67,377,281...67,697,256
|
|
G |
PKNOX2 |
PBX/knotted 1 homeobox 2 |
decreases expression |
ISO |
Carmustine results in decreased expression of PKNOX2 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr11:125,164,751...125,433,389
Ensembl chr11:125,164,687...125,433,389
|
|
G |
PKP2 |
plakophilin 2 |
increases expression |
ISO |
Carmustine results in increased expression of PKP2 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr12:32,790,755...32,896,777
Ensembl chr12:32,790,745...32,896,798
|
|
G |
PKP3 |
plakophilin 3 |
affects response to substance |
EXP |
PKP3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr11:392,596...404,908
Ensembl chr11:392,614...404,908
|
|
G |
PLEKHG5 |
pleckstrin homology and RhoGEF domain containing G5 |
affects response to substance |
EXP |
PLEKHG5 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:6,467,122...6,520,092
Ensembl chr 1:6,467,122...6,520,074
|
|
G |
PNPLA2 |
patatin like phospholipase domain containing 2 |
increases expression |
ISO |
Carmustine results in increased expression of PNPLA2 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr11:818,914...825,573
Ensembl chr11:818,914...825,573
|
|
G |
POLG2 |
DNA polymerase gamma 2, accessory subunit |
affects response to substance |
EXP |
POLG2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr17:64,477,785...64,497,054
Ensembl chr17:64,477,785...64,497,054
|
|
G |
POLH |
DNA polymerase eta |
multiple interactions |
EXP |
[Carmustine co-treated with MDM4 protein] results in increased expression of POLH protein |
CTD |
PMID:20472715 |
|
NCBI chr 6:43,576,185...43,620,523
Ensembl chr 6:43,576,185...43,620,523
|
|
G |
POLR2E |
RNA polymerase II, I and III subunit E |
decreases expression |
EXP |
Carmustine results in decreased expression of POLR2E mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:1,086,574...1,095,375
Ensembl chr19:1,086,574...1,095,380
|
|
G |
POPDC3 |
popeye domain cAMP effector 3 |
affects response to substance |
EXP |
POPDC3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 6:105,157,900...105,180,014
Ensembl chr 6:105,157,900...105,180,014
|
|
G |
PPM1G |
protein phosphatase, Mg2+/Mn2+ dependent 1G |
decreases expression |
EXP |
Carmustine results in decreased expression of PPM1G mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 2:27,381,199...27,409,591
Ensembl chr 2:27,381,195...27,409,591
|
|
G |
PRC1 |
protein regulator of cytokinesis 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of PRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr15:90,966,040...90,994,535
Ensembl chr15:90,966,040...90,995,629
|
|
G |
PREX1 |
phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 |
affects response to substance |
EXP |
PREX1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr20:48,624,252...48,888,185
Ensembl chr20:48,624,252...48,827,999
|
|
G |
PRKAA2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
affects response to substance |
EXP |
PRKAA2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:56,645,314...56,715,335
Ensembl chr 1:56,645,314...56,715,335
|
|
G |
PRL |
prolactin |
decreases expression |
EXP |
Carmustine results in decreased expression of PRL mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 6:22,287,246...22,302,835
Ensembl chr 6:22,287,244...22,302,826
|
|
G |
PRM2 |
protamine 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of PRM2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr16:11,275,639...11,276,480
Ensembl chr16:11,275,639...11,276,480
|
|
G |
PRPH |
peripherin |
decreases expression |
ISO |
Carmustine results in decreased expression of PRPH mRNA |
CTD |
PMID:16005536 |
|
NCBI chr12:49,295,147...49,298,686
Ensembl chr12:49,295,147...49,298,686
|
|
G |
PRRX2 |
paired related homeobox 2 |
affects response to substance |
EXP |
PRRX2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 9:129,665,647...129,722,674
Ensembl chr 9:129,665,647...129,722,674
|
|
G |
PRSS12 |
serine protease 12 |
affects response to substance |
EXP |
PRSS12 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 4:118,280,038...118,353,003
Ensembl chr 4:118,280,038...118,353,003
|
|
G |
PTH2R |
parathyroid hormone 2 receptor |
decreases expression |
ISO |
Carmustine results in decreased expression of PTH2R mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 2:208,359,692...208,494,506
Ensembl chr 2:208,359,714...208,854,503
|
|
G |
PTPN3 |
protein tyrosine phosphatase non-receptor type 3 |
decreases expression |
EXP |
Carmustine results in decreased expression of PTPN3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 9:109,375,694...109,538,420
Ensembl chr 9:109,375,466...109,498,313
|
|
G |
PZP |
PZP alpha-2-macroglobulin like |
decreases expression |
EXP |
Carmustine results in decreased expression of PZP mRNA |
CTD |
PMID:15980968 |
|
NCBI chr12:9,136,472...9,208,395
Ensembl chr12:9,148,840...9,208,395
|
|
G |
QPCT |
glutaminyl-peptide cyclotransferase |
affects response to substance |
EXP |
QPCT mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 2:37,344,630...37,373,322
Ensembl chr 2:37,342,827...37,373,322
|
|
G |
RAB27B |
RAB27B, member RAS oncogene family |
affects response to substance |
EXP |
RAB27B mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr18:54,717,857...54,895,516
Ensembl chr18:54,717,860...54,895,516
|
|
G |
RAD23A |
RAD23 homolog A, nucleotide excision repair protein |
decreases expression |
EXP |
Carmustine results in decreased expression of RAD23A mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:12,945,862...12,953,642
Ensembl chr19:12,945,855...12,953,642
|
|
G |
RAD51 |
RAD51 recombinase |
decreases expression |
EXP |
Carmustine results in decreased expression of RAD51 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr15:40,694,733...40,732,340
Ensembl chr15:40,694,774...40,732,340
|
|
G |
RAD9A |
RAD9 checkpoint clamp component A |
decreases expression |
EXP |
Carmustine results in decreased expression of RAD9A mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:67,391,986...67,398,412
Ensembl chr11:67,317,871...67,398,410
|
|
G |
RBM19 |
RNA binding motif protein 19 |
affects response to substance |
EXP |
RBM19 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr12:113,816,740...113,966,325
Ensembl chr12:113,816,738...113,966,325
|
|
G |
RCN1 |
reticulocalbin 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of RCN1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:32,091,074...32,105,722
Ensembl chr11:32,091,074...32,105,722
|
|
G |
REL |
REL proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Carmustine inhibits the reaction [Lipopolysaccharides affects the localization of REL protein] |
CTD |
PMID:11970852 PMID:12433058 |
|
NCBI chr 2:60,881,574...60,931,612
Ensembl chr 2:60,881,491...60,931,612
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
Carmustine results in increased activity of [NFKB1 protein binds to RELA protein]; NFKBIA gene mutant form inhibits the reaction [Carmustine results in increased activity of [NFKB1 protein binds to RELA protein]] Carmustine inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Carmustine inhibits the reaction [Lipopolysaccharides results in increased activity of [NFKB1 protein binds to RELA protein]] [Carmustine co-treated with Oligodeoxyribonucleotides analog] results in increased activity of [NFKB1 protein binds to RELA protein]; diphenyleneiodonium inhibits the reaction [[Carmustine co-treated with Oligodeoxyribonucleotides analog] results in increased activity of [NFKB1 protein binds to RELA protein]] |
CTD |
PMID:11970852 PMID:12433058 PMID:12477282 PMID:12675310 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RELB |
RELB proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Carmustine inhibits the reaction [Lipopolysaccharides affects the localization of RELB protein] |
CTD |
PMID:11970852 PMID:12433058 |
|
NCBI chr19:45,001,464...45,038,192
Ensembl chr19:45,001,461...45,038,192
|
|
G |
RFC3 |
replication factor C subunit 3 |
decreases expression |
ISO |
Carmustine results in decreased expression of RFC3 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr13:33,818,149...33,977,377
Ensembl chr13:33,818,069...33,966,558
|
|
G |
RGCC |
regulator of cell cycle |
affects response to substance |
EXP |
RGCC mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr13:41,457,550...41,470,871
Ensembl chr13:41,457,550...41,470,871
|
|
G |
RGP1 |
RGP1 homolog, RAB6A GEF complex partner 1 |
affects response to substance |
EXP |
RGP1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 9:35,749,287...35,790,428
Ensembl chr 9:35,749,287...35,758,585
|
|
G |
RGR |
retinal G protein coupled receptor |
decreases expression |
EXP |
Carmustine results in decreased expression of RGR mRNA |
CTD |
PMID:15980968 |
|
NCBI chr10:84,245,053...84,259,960
Ensembl chr10:84,230,666...84,259,960
|
|
G |
RHOBTB3 |
Rho related BTB domain containing 3 |
affects response to substance |
EXP |
RHOBTB3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 5:95,717,624...95,796,361
Ensembl chr 5:95,713,522...95,824,383
|
|
G |
RIT2 |
Ras like without CAAX 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of RIT2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr18:42,743,227...43,115,685
Ensembl chr18:42,743,227...43,115,691
|
|
G |
RNASE4 |
ribonuclease A family member 4 |
increases expression |
EXP |
Carmustine results in increased expression of RNASE4 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr14:20,684,560...20,701,216
Ensembl chr14:20,684,560...20,701,216
|
|
G |
RORB |
RAR related orphan receptor B |
affects expression |
ISO |
Carmustine affects the expression of RORB mRNA |
CTD |
PMID:19174181 |
|
NCBI chr 9:74,497,335...74,693,177
Ensembl chr 9:74,497,335...74,693,177
|
|
G |
S1PR3 |
sphingosine-1-phosphate receptor 3 |
affects response to substance |
EXP |
S1PR3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 9:88,990,863...89,005,155
Ensembl chr 9:88,990,863...89,005,155
|
|
G |
SAT1 |
spermidine/spermine N1-acetyltransferase 1 |
affects response to substance |
EXP |
SAT1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr X:23,783,173...23,786,210
Ensembl chr X:23,783,173...23,786,210
|
|
G |
SCAMP5 |
secretory carrier membrane protein 5 |
affects response to substance |
EXP |
SCAMP5 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr15:74,995,563...75,021,495
Ensembl chr15:74,957,219...75,021,495
|
|
G |
SCN1B |
sodium voltage-gated channel beta subunit 1 |
increases expression |
ISO |
Carmustine results in increased expression of SCN1B mRNA |
CTD |
PMID:16005536 |
|
NCBI chr19:35,030,470...35,040,449
Ensembl chr19:35,030,470...35,040,449
|
|
G |
SCN8A |
sodium voltage-gated channel alpha subunit 8 |
affects response to substance |
EXP |
SCN8A mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr12:51,591,233...51,812,864
Ensembl chr12:51,590,266...51,812,864
|
|
G |
SDC1 |
syndecan 1 |
affects response to substance |
EXP |
SDC1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 2:20,200,797...20,225,475
Ensembl chr 2:20,200,797...20,225,433
|
|
G |
SEMA3A |
semaphorin 3A |
affects response to substance |
EXP |
SEMA3A mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 7:83,955,777...84,492,725
Ensembl chr 7:83,955,777...84,492,724
|
|
G |
SEPTIN4 |
septin 4 |
decreases expression |
ISO |
Carmustine results in decreased expression of SEPTIN4 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr17:58,520,256...58,544,328
Ensembl chr17:58,520,250...58,544,368
|
|
G |
SEPTIN5 |
septin 5 |
decreases expression |
EXP |
Carmustine results in decreased expression of SEPTIN5 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr22:19,714,503...19,723,319
Ensembl chr22:19,714,503...19,724,224
|
|
G |
SERPINB1 |
serpin family B member 1 |
affects response to substance |
EXP |
SERPINB1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 6:2,832,332...2,841,863
Ensembl chr 6:2,832,332...2,841,959
|
|
G |
SF1 |
splicing factor 1 |
affects response to substance |
EXP |
SF1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr11:64,764,606...64,778,542
Ensembl chr11:64,764,606...64,778,786
|
|
G |
SFPQ |
splicing factor proline and glutamine rich |
decreases expression |
EXP |
Carmustine results in decreased expression of SFPQ mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:35,176,380...35,193,145
Ensembl chr 1:35,176,378...35,193,446
|
|
G |
SGCA |
sarcoglycan alpha |
decreases expression |
EXP |
Carmustine results in decreased expression of SGCA mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:50,166,005...50,175,928
Ensembl chr17:50,164,214...50,175,928
|
|
G |
SHMT2 |
serine hydroxymethyltransferase 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of SHMT2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr12:57,229,711...57,234,935
Ensembl chr12:57,229,573...57,234,935
|
|
G |
SHOX |
SHOX homeobox |
decreases expression |
EXP |
Carmustine results in decreased expression of SHOX mRNA |
CTD |
PMID:15980968 |
|
NCBI chr Y:624,344...659,411 NCBI chr X:624,344...659,411
Ensembl chr Y:624,344...659,411 Ensembl chr X:624,344...659,411
|
|
G |
SLC10A1 |
solute carrier family 10 member 1 |
increases expression |
EXP |
Carmustine results in increased expression of SLC10A1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
|
|
G |
SLC12A1 |
solute carrier family 12 member 1 |
decreases expression |
ISO |
Carmustine results in decreased expression of SLC12A1 mRNA |
CTD |
PMID:17727784 |
|
NCBI chr15:48,206,302...48,304,078
Ensembl chr15:48,178,438...48,304,078
|
|
G |
SLC12A2 |
solute carrier family 12 member 2 |
increases expression |
ISO |
Carmustine results in increased expression of SLC12A2 mRNA |
CTD |
PMID:17727784 |
|
NCBI chr 5:128,083,766...128,189,677
Ensembl chr 5:128,083,766...128,189,677
|
|
G |
SLC14A1 |
solute carrier family 14 member 1 (Kidd blood group) |
affects response to substance |
EXP |
SLC14A1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr18:45,724,181...45,752,520
Ensembl chr18:45,687,025...45,752,520
|
|
G |
SLC15A2 |
solute carrier family 15 member 2 |
affects response to substance |
EXP |
SLC15A2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 3:121,894,401...121,944,188
Ensembl chr 3:121,894,401...121,944,188
|
|
G |
SLC16A2 |
solute carrier family 16 member 2 |
increases expression |
EXP |
Carmustine results in increased expression of SLC16A2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr X:74,421,493...74,533,916
Ensembl chr X:74,421,493...74,533,917
|
|
G |
SLC19A2 |
solute carrier family 19 member 2 |
decreases expression |
ISO |
Carmustine results in decreased expression of SLC19A2 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 1:169,463,909...169,485,970
Ensembl chr 1:169,463,909...169,485,944
|
|
G |
SLC22A5 |
solute carrier family 22 member 5 |
affects response to substance |
EXP |
SLC22A5 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 5:132,369,710...132,395,612
Ensembl chr 5:132,369,710...132,395,613
|
|
G |
SLC30A3 |
solute carrier family 30 member 3 |
decreases expression |
EXP |
Carmustine results in decreased expression of SLC30A3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 2:27,253,684...27,275,817
Ensembl chr 2:27,253,684...27,275,817
|
|
G |
SLC3A2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
Carmustine results in increased expression of SLC3A2 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr11:62,856,109...62,888,860
Ensembl chr11:62,856,004...62,888,880
|
|
G |
SLC6A2 |
solute carrier family 6 member 2 |
increases expression |
EXP |
Carmustine results in increased expression of SLC6A2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr16:55,655,988...55,706,192
Ensembl chr16:55,655,988...55,707,645
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
decreases expression |
EXP |
Carmustine results in decreased expression of SLCO1A2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr12:21,264,600...21,419,634
Ensembl chr12:21,264,600...21,419,594
|
|
G |
SLPI |
secretory leukocyte peptidase inhibitor |
affects response to substance |
EXP |
SLPI mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr20:45,252,239...45,254,564
Ensembl chr20:45,252,239...45,254,564
|
|
G |
SMARCD1 |
SWI/SNF related BAF chromatin remodeling complex subunit D1 |
increases expression |
EXP |
Carmustine results in increased expression of SMARCD1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr12:50,085,342...50,100,707
Ensembl chr12:50,085,200...50,100,707
|
|
G |
SMPD2 |
sphingomyelin phosphodiesterase 2 |
increases expression |
EXP |
Carmustine results in increased expression of SMPD2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 6:109,440,724...109,443,919
Ensembl chr 6:109,440,724...109,443,919
|
|
G |
SNAPC1 |
small nuclear RNA activating complex polypeptide 1 |
increases expression |
EXP |
Carmustine results in increased expression of SNAPC1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr14:61,762,420...61,796,428
Ensembl chr14:61,762,420...61,796,428
|
|
G |
SNAPC3 |
small nuclear RNA activating complex polypeptide 3 |
increases expression |
EXP |
Carmustine results in increased expression of SNAPC3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 9:15,422,876...15,466,735
Ensembl chr 9:15,422,734...15,465,953
|
|
G |
SNCG |
synuclein gamma |
increases expression |
EXP |
Carmustine results in increased expression of SNCG mRNA |
CTD |
PMID:15980968 |
|
NCBI chr10:86,955,759...86,963,258
Ensembl chr10:86,958,599...86,963,258
|
|
G |
SNRPB2 |
small nuclear ribonucleoprotein polypeptide B2 |
increases expression |
EXP |
Carmustine results in increased expression of SNRPB2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr20:16,730,026...16,742,564
Ensembl chr20:16,729,961...16,742,564
|
|
G |
SOCS1 |
suppressor of cytokine signaling 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of SOCS1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr16:11,254,417...11,256,204
Ensembl chr16:11,254,417...11,256,204
|
|
G |
SOD1 |
superoxide dismutase 1 |
decreases activity |
EXP |
Carmustine results in decreased activity of SOD1 protein |
CTD |
PMID:19856331 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SOD2 |
superoxide dismutase 2 |
affects response to substance increases response to substance multiple interactions decreases activity |
EXP |
SOD2 mRNA affects the susceptibility to Carmustine SOD2 protein results in increased susceptibility to Carmustine Pyruvates inhibits the reaction [SOD2 protein results in increased susceptibility to Carmustine] Carmustine results in decreased activity of SOD2 protein |
CTD |
PMID:8877099 PMID:16365179 PMID:19856331 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SORBS2 |
sorbin and SH3 domain containing 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of SORBS2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 4:185,585,523...185,956,372
Ensembl chr 4:185,585,444...185,956,652
|
|
G |
SOX9 |
SRY-box transcription factor 9 |
affects response to substance |
EXP |
SOX9 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416
|
|
G |
SPARC |
secreted protein acidic and cysteine rich |
affects response to substance |
EXP |
SPARC mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 5:151,661,096...151,686,915
Ensembl chr 5:151,661,096...151,686,975
|
|
G |
SPATA12 |
spermatogenesis associated 12 |
affects response to substance |
EXP |
SPATA12 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 3:57,060,664...57,075,432
Ensembl chr 3:57,060,664...57,075,432
|
|
G |
SPEG |
striated muscle enriched protein kinase |
decreases expression |
EXP |
Carmustine results in decreased expression of SPEG mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 2:219,434,843...219,493,629
Ensembl chr 2:219,434,843...219,493,629
|
|
G |
SPEN |
spen family transcriptional repressor |
affects response to substance |
EXP |
SPEN mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:15,847,707...15,940,456
Ensembl chr 1:15,836,095...15,940,456
|
|
G |
SPRR2B |
small proline rich protein 2B |
decreases expression |
EXP |
Carmustine results in decreased expression of SPRR2B mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:153,070,226...153,087,799
Ensembl chr 1:153,070,226...153,071,611
|
|
G |
SQLE |
squalene epoxidase |
affects response to substance |
EXP |
SQLE mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 8:124,998,505...125,022,283
Ensembl chr 8:124,998,497...125,022,283
|
|
G |
SRP14 |
signal recognition particle 14 |
decreases expression |
EXP |
Carmustine results in decreased expression of SRP14 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr15:40,035,690...40,039,202
Ensembl chr15:40,035,690...40,039,181
|
|
G |
SRY |
sex determining region Y |
decreases expression |
EXP |
Carmustine results in decreased expression of SRY mRNA |
CTD |
PMID:15980968 |
|
NCBI chr Y:2,786,855...2,787,682
Ensembl chr Y:2,786,855...2,787,682
|
|
G |
ST3GAL1 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 |
affects response to substance |
EXP |
ST3GAL1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 8:133,454,848...133,571,887
Ensembl chr 8:133,454,848...133,571,926
|
|
G |
ST6GAL1 |
ST6 beta-galactoside alpha-2,6-sialyltransferase 1 |
increases expression |
EXP |
Carmustine results in increased expression of ST6GAL1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 3:186,930,526...187,078,553
Ensembl chr 3:186,930,325...187,078,553
|
|
G |
ST8SIA1 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 |
increases expression |
EXP |
Carmustine results in increased expression of ST8SIA1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr12:22,193,391...22,334,707
Ensembl chr12:22,063,773...22,437,041
|
|
G |
STAM |
signal transducing adaptor molecule |
decreases expression |
EXP |
Carmustine results in decreased expression of STAM mRNA |
CTD |
PMID:15980968 |
|
NCBI chr10:17,644,151...17,716,824
Ensembl chr10:17,644,151...17,716,824
|
|
G |
STC1 |
stanniocalcin 1 |
affects response to substance |
EXP |
STC1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 8:23,841,929...23,854,806
Ensembl chr 8:23,841,929...23,854,806
|
|
G |
STMN1 |
stathmin 1 |
affects response to substance |
EXP |
STMN1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:17440165 |
|
NCBI chr 1:25,884,179...25,906,880
Ensembl chr 1:25,884,181...25,906,991
|
|
G |
STS |
steroid sulfatase |
increases expression |
EXP |
Carmustine results in increased expression of STS mRNA |
CTD |
PMID:15980968 |
|
NCBI chr X:7,147,290...7,354,641
Ensembl chr X:7,147,237...7,804,358
|
|
G |
STX1B |
syntaxin 1B |
decreases expression |
EXP |
Carmustine results in decreased expression of STX1B mRNA |
CTD |
PMID:15980968 |
|
NCBI chr16:30,989,256...31,010,638
Ensembl chr16:30,989,256...31,010,638
|
|
G |
STXBP2 |
syntaxin binding protein 2 |
decreases expression |
EXP |
Carmustine results in decreased expression of STXBP2 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:7,629,793...7,647,873
Ensembl chr19:7,636,772...7,647,873
|
|
G |
STXBP6 |
syntaxin binding protein 6 |
affects response to substance |
EXP |
STXBP6 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr14:24,809,454...25,050,147
Ensembl chr14:24,809,454...25,050,147
|
|
G |
SYNPO2 |
synaptopodin 2 |
affects response to substance |
EXP |
SYNPO2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 4:118,850,681...119,061,247
Ensembl chr 4:118,850,688...119,061,247
|
|
G |
SYP |
synaptophysin |
multiple interactions decreases expression |
ISO |
Melatonin inhibits the reaction [Carmustine results in decreased expression of SYP protein] |
CTD |
PMID:17572393 |
|
NCBI chr X:49,187,815...49,200,193
Ensembl chr X:49,187,815...49,200,218
|
|
G |
TAC1 |
tachykinin precursor 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of TAC1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 7:97,732,086...97,740,472
Ensembl chr 7:97,732,084...97,740,472
|
|
G |
TAGLN |
transgelin |
affects response to substance |
EXP |
TAGLN mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr11:117,199,294...117,207,465
Ensembl chr11:117,199,370...117,207,464
|
|
G |
TBX3 |
T-box transcription factor 3 |
affects response to substance |
EXP |
TBX3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr12:114,670,255...114,684,175
Ensembl chr12:114,670,255...114,684,175
|
|
G |
TCF21 |
transcription factor 21 |
decreases expression |
EXP |
Carmustine results in decreased expression of TCF21 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 6:133,889,113...133,895,537
Ensembl chr 6:133,889,113...133,895,553
|
|
G |
TCIM |
transcriptional and immune response regulator |
increases response to substance |
EXP |
TCIM mRNA results in increased susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 8:40,153,482...40,155,310
Ensembl chr 8:40,153,482...40,155,310
|
|
G |
TDRP |
testis development related protein |
affects response to substance |
EXP |
TDRP mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 8:489,946...545,780
Ensembl chr 8:489,803...545,781
|
|
G |
TERT |
telomerase reverse transcriptase |
decreases response to substance |
EXP |
TERT protein mutant form results in decreased susceptibility to Carmustine |
CTD |
PMID:12488552 |
|
NCBI chr 5:1,253,167...1,295,068
Ensembl chr 5:1,253,147...1,295,068
|
|
G |
TFAP2C |
transcription factor AP-2 gamma |
affects response to substance |
EXP |
TFAP2C mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr20:56,629,306...56,639,283
Ensembl chr20:56,629,306...56,639,283
|
|
G |
TFDP1 |
transcription factor Dp-1 |
affects response to substance |
EXP |
TFDP1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr13:113,584,688...113,641,473
Ensembl chr13:113,584,721...113,641,473
|
|
G |
TFPI2 |
tissue factor pathway inhibitor 2 |
affects response to substance |
EXP |
TFPI2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 7:93,885,396...93,890,753
Ensembl chr 7:93,885,396...93,890,753
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions decreases expression |
ISO |
Melatonin inhibits the reaction [Carmustine results in decreased expression of TGFB1 protein] |
CTD |
PMID:17572393 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TH |
tyrosine hydroxylase |
increases activity increases expression |
ISO |
Carmustine results in increased activity of TH protein Carmustine results in increased expression of TH mRNA; Carmustine results in increased expression of TH protein |
CTD |
PMID:14670008 |
|
NCBI chr11:2,163,929...2,171,815
Ensembl chr11:2,163,929...2,171,815
|
|
G |
THBD |
thrombomodulin |
affects response to substance |
EXP |
THBD mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr20:23,045,633...23,049,672
Ensembl chr20:23,045,633...23,049,672
|
|
G |
TLE3 |
TLE family member 3, transcriptional corepressor |
decreases expression |
EXP |
Carmustine results in decreased expression of TLE3 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr15:70,047,790...70,097,917
Ensembl chr15:70,047,790...70,098,176
|
|
G |
TMEM158 |
transmembrane protein 158 |
affects response to substance |
EXP |
TMEM158 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 3:45,224,466...45,226,287
Ensembl chr 3:45,224,466...45,226,287
|
|
G |
TMEM19 |
transmembrane protein 19 |
affects response to substance |
EXP |
TMEM19 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr12:71,686,082...71,705,047
Ensembl chr12:71,686,082...71,705,047
|
|
G |
TMPRSS15 |
transmembrane serine protease 15 |
affects response to substance |
EXP |
TMPRSS15 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr21:18,269,116...18,485,884
Ensembl chr21:18,269,116...18,485,879
|
|
G |
TNC |
tenascin C |
affects response to substance |
EXP |
TNC mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 9:115,019,575...115,118,157
Ensembl chr 9:115,019,575...115,118,207
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions increases expression |
ISO |
[Carmustine co-treated with 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid] inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitrites]; [Carmustine co-treated with Buthionine Sulfoximine] inhibits the reaction [TNF protein results in increased expression of NOS2 protein]; Buthionine Sulfoximine promotes the reaction [Carmustine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]]; Carmustine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]; Carmustine promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; MT2 protein inhibits the reaction [Carmustine results in increased expression of TNF protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Carmustine]; Zinc Sulfate inhibits the reaction [Carmustine results in increased expression of TNF protein] Carmustine promotes the reaction [Oligodeoxyribonucleotides analog results in increased secretion of TNF protein] |
CTD |
PMID:7532384 PMID:11970852 PMID:12433058 PMID:12477282 PMID:18528683 PMID:20046642 More...
|
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFAIP3 |
TNF alpha induced protein 3 |
increases response to substance |
EXP |
TNFAIP3 mRNA results in increased susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 6:137,866,349...137,883,312
Ensembl chr 6:137,867,214...137,883,314
|
|
G |
TNFRSF11B |
TNF receptor superfamily member 11b |
decreases expression |
EXP |
Carmustine results in decreased expression of TNFRSF11B mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 8:118,923,557...118,951,885
Ensembl chr 8:118,923,557...118,951,885
|
|
G |
TNFRSF19 |
TNF receptor superfamily member 19 |
affects response to substance |
EXP |
TNFRSF19 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr13:23,570,412...23,676,093
Ensembl chr13:23,570,370...23,676,104
|
|
G |
TNFSF10 |
TNF superfamily member 10 |
affects response to substance |
EXP |
TNFSF10 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions increases expression increases response to substance decreases response to substance affects response to substance |
EXP |
[Carmustine co-treated with O(6)-benzylguanine] results in increased expression of TP53 protein; MDM4 protein promotes the reaction [Carmustine results in increased expression of TP53 protein] TP53 results in increased susceptibility to Carmustine TP53 protein results in decreased susceptibility to Carmustine TP53 protein modified form affects the susceptibility to Carmustine |
CTD |
PMID:10455409 PMID:11861384 PMID:15735757 PMID:16193384 PMID:18632648 PMID:20472715 More...
|
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
G |
TPD52L1 |
TPD52 like 1 |
affects response to substance |
EXP |
TPD52L1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 6:125,153,773...125,264,407
Ensembl chr 6:125,119,049...125,264,407
|
|
G |
TRAF1 |
TNF receptor associated factor 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of TRAF1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 9:120,902,393...120,929,171
Ensembl chr 9:120,902,393...120,929,173
|
|
G |
TREX1 |
three prime repair exonuclease 1 |
increases expression |
EXP |
Carmustine results in increased expression of TREX1 mRNA |
CTD |
PMID:23578789 |
|
NCBI chr 3:48,465,830...48,467,645
Ensembl chr 3:48,465,811...48,467,645
|
|
G |
TRIM50 |
tripartite motif containing 50 |
affects response to substance |
EXP |
TRIM50 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 7:73,312,536...73,328,082
Ensembl chr 7:73,312,536...73,328,082
|
|
G |
TSPAN4 |
tetraspanin 4 |
decreases expression |
EXP |
Carmustine results in decreased expression of TSPAN4 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr11:842,852...867,111
Ensembl chr11:842,812...867,116
|
|
G |
TUBB |
tubulin beta class I |
increases expression |
EXP |
Carmustine results in increased expression of TUBB mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 6:30,720,352...30,725,422
Ensembl chr 6:30,717,435...30,725,538
|
|
G |
TUBG1 |
tubulin gamma 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of TUBG1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr17:42,609,683...42,615,238
Ensembl chr17:42,609,641...42,615,238
|
|
G |
TUFM |
Tu translation elongation factor, mitochondrial |
affects response to substance |
EXP |
TUFM mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr16:28,842,411...28,846,348
Ensembl chr16:28,842,411...28,846,348
|
|
G |
TULP3 |
TUB like protein 3 |
affects response to substance |
EXP |
TULP3 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr12:2,890,891...2,941,138
Ensembl chr12:2,877,223...2,941,138
|
|
G |
TXNRD1 |
thioredoxin reductase 1 |
multiple interactions decreases activity |
ISO |
[Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of TXNRD1 protein Carmustine results in decreased activity of TXNRD1 protein |
CTD |
PMID:16085187 PMID:16288907 |
|
NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307
|
|
G |
UGT8 |
UDP glycosyltransferase 8 |
increases expression |
EXP |
Carmustine results in increased expression of UGT8 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 4:114,598,402...114,678,225
Ensembl chr 4:114,598,770...114,678,588
|
|
G |
UPF1 |
UPF1 RNA helicase and ATPase |
decreases expression |
EXP |
Carmustine results in decreased expression of UPF1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr19:18,831,959...18,868,230
Ensembl chr19:18,831,959...18,868,230
|
|
G |
VAMP4 |
vesicle associated membrane protein 4 |
affects response to substance |
EXP |
VAMP4 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:171,700,160...171,742,065
Ensembl chr 1:171,700,160...171,742,074
|
|
G |
VAT1L |
vesicle amine transport 1 like |
affects response to substance |
EXP |
VAT1L mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr16:77,788,564...77,980,107
Ensembl chr16:77,788,564...77,980,107
|
|
G |
VGF |
VGF nerve growth factor inducible |
decreases expression |
EXP |
Carmustine results in decreased expression of VGF mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 7:101,162,509...101,169,952
Ensembl chr 7:101,162,509...101,165,569
|
|
G |
VLDLR |
very low density lipoprotein receptor |
affects response to substance |
EXP |
VLDLR mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 9:2,621,787...2,660,056
Ensembl chr 9:2,621,182...2,660,056
|
|
G |
WASF2 |
WASP family member 2 |
affects response to substance |
EXP |
WASF2 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 1:27,404,230...27,490,167
Ensembl chr 1:27,404,230...27,490,167
|
|
G |
WFDC1 |
WAP four-disulfide core domain 1 |
affects response to substance |
EXP |
WFDC1 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr16:84,294,878...84,329,844
Ensembl chr16:84,294,846...84,329,844
|
|
G |
WIPF1 |
WAS/WASL interacting protein family member 1 |
decreases expression |
EXP |
Carmustine results in decreased expression of WIPF1 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 2:174,559,574...174,682,913
Ensembl chr 2:174,559,572...174,682,916
|
|
G |
WNT5A |
Wnt family member 5A |
affects response to substance |
EXP |
WNT5A mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 3:55,465,715...55,505,263
Ensembl chr 3:55,465,715...55,490,539
|
|
G |
WT1 |
WT1 transcription factor |
decreases response to substance |
EXP |
WT1 results in decreased susceptibility to Carmustine |
CTD |
PMID:20820871 |
|
NCBI chr11:32,387,775...32,435,539
Ensembl chr11:32,387,775...32,435,564
|
|
G |
YWHAH |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta |
decreases expression |
EXP |
Carmustine results in decreased expression of YWHAH mRNA |
CTD |
PMID:15980968 |
|
NCBI chr22:31,944,535...31,957,603
Ensembl chr22:31,944,522...31,957,603
|
|
G |
ZBTB17 |
zinc finger and BTB domain containing 17 |
decreases expression |
EXP |
Carmustine results in decreased expression of ZBTB17 mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 1:15,941,869...15,976,101
Ensembl chr 1:15,941,869...15,976,132
|
|
G |
ZC3H13 |
zinc finger CCCH-type containing 13 |
affects response to substance |
EXP |
ZC3H13 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr13:45,954,465...46,052,746
Ensembl chr13:45,954,465...46,052,759
|
|
G |
ZNF112 |
zinc finger protein 112 |
affects response to substance |
EXP |
ZNF112 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr19:44,326,553...44,367,217
Ensembl chr19:44,326,555...44,367,217
|
|
G |
ZNF189 |
zinc finger protein 189 |
increases expression |
ISO |
Carmustine results in increased expression of ZNF189 mRNA |
CTD |
PMID:16005536 |
|
NCBI chr 9:101,398,851...101,410,654
Ensembl chr 9:101,398,851...101,410,660
|
|
G |
ZNF655 |
zinc finger protein 655 |
affects response to substance |
EXP |
ZNF655 mRNA affects the susceptibility to Carmustine |
CTD |
PMID:16365179 |
|
NCBI chr 7:99,558,642...99,576,453
Ensembl chr 7:99,558,406...99,576,453
|
|
G |
ZYX |
zyxin |
decreases expression |
EXP |
Carmustine results in decreased expression of ZYX mRNA |
CTD |
PMID:15980968 |
|
NCBI chr 7:143,381,345...143,391,111
Ensembl chr 7:143,381,295...143,391,111
|
|